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Abstract 
 Blockade of immune cell adhesion during antigen recognition may suppress the 
inflammatory immune response in autoimmune diseases.  Employing a novel N-oxime 
chemistry, Soluble Antigen Arrays (SAgAs) were synthesized to simultaneously display 
intracellular cell-adhesion molecule-1 (ICAM-1) inhibitor and antigen. Hyaluronic acid (HA) was 
used as a backbone and two peptides were grafted, an ICAM-1 inhibitor (LABL) derived from αL-
integrin and an encephalitogenic epitope of proteolipid protein (PLP).  Mice with experimental 
autoimmune encephalomyelitis (EAE) that received subcutaneous (s.c.) injections of SAgAs 
displaying both peptides showed significantly lower clinical disease scores and incidence, as 
well as better body weight maintenance than those treated with HA polymer alone. Multivalent 
presentation of cell-adhesion inhibitor (LABL) alone or antigen (PLP) alone was also evaluated.  
Treatment with hyaluronic acid grafted with only PLP antigen or only LABL peptide did not 
provide significant disease suppression and, in the case of LABL, actually exacerbated the 
disease.  When hyaluronic acid was replaced with a PLGA nanoparticle displaying grafted LABL 
and PLP (NP-ArrayLABL-PLP), an analogous treatment strategy with the NP-ArrayLABL-PLP did not 
provide significant EAE suppression.   
 Next, the effect of SAgA molecular weight and cell-adhesion molecule target were 
evaluated.  SAgAs with inhibitors targeting intracellular cell-adhesion molecule-1 (ICAM-1) or its 
ligand leukocyte-associated function antigen-1 (LFA-1) were equally effective.  Also, the disease 
onset was delayed and severity was significantly reduced when the molecular weight of the 
SAgA was decreased.   Animal imaging suggested that the smaller SAgA drained from the 
injection site more quickly than the larger SAgA, which may suggest enhanced transit to the 
regional lymphatics.  Analysis of the cytokine production profiles of all treatments demonstrated 
that reducing SAgA size also provided the largest change in inflammatory cytokine response.  
SAgA performance, therefore, depended on lymphatic drainage as dictated by size, as well as 
molecular signaling resulting from co-grafting cell-adhesion inhibitor and antigen.  Future 
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research should attempt to correlate SAgA transport with efficacy and explore the effect of 
grafting different inhibitors or activators of co-stimulation. 
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Chapter 1 
Background and Introduction to Thesis 
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1.1 Nanomaterials and Immune Response 
The use of nanomaterials such as polymers and colloids in medicine and biotechnology 
has grown dramatically over the past two decades. (1)  While the applications vary greatly, 
many have explored the ability of these materials to generate an immune response.  
Nanomaterials have been used in vaccines to invoke a protective immune response, but less 
work has explored features for inducing tolerance. (2-3)  The effect of particle size, drug loading, 
and toxicity of these materials is well documented for specific applications. (3)  Outside of 
particle size however, the effect of nanomaterial physical characteristics and route of 
administration on transport, final deposition site, and immune response merits further 
exploration.  In particular, research must probe the ability of nanomaterials presenting small 
molecules, peptides, or other haptens on or along their surface to illicit specific and sustained 
immune responses.   
The importance of physical presentation of antigen is a well-documented effector of 
vaccine efficacy.  Adjuvants are used to help generate immune responses against the delivered 
antigen and the way an adjuvant interacts with an antigen (e.g. surface adsorption, changes in 
protein folding, antigen epitope stability, and/or the physical formulation of the vaccine) is crucial 
to establishing potency and long term efficacy. (4-5)  Even small changes to any of these factors 
can result in dramatic decreases in the clinical efficacy. (5)  The physical and chemical context 
of antigen presentation is an important determinant of a vaccine’s ability to generate an 
inflammatory response and achieve sustained immune protection.   
Dintzis and others investigated the immune response to nanomaterials displaying 
multiple copies of grafted antigen, which demonstrated the importance of physical presentation 
on the magnitude and type of immune response.  Dintzis developed “rules” for antigen-grafted 
polymers by manipulating grafting characteristics of small molecule or peptide haptens along 
flexible polymer chains, correlating structure to the immune response. (6-9)  Using ‘arrays’ of 
antigen grafted to polymers ranging in size from 3 to 500 kDa, Dintzis systematically 
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investigated the role that valency played on the material’s ability to initiate specific immune 
responses.  While the smaller arrays (~30 kDa) had a low binding avidity in vitro, they were 
typically more efficient in generating a tolerogenic immune response in vivo. (10)  Dintzis 
hypothesized that array size played a role in differential signal transduction induced by the 
arrays on a cellular level.  Building on these results, it was demonstrated that immune response 
could favor expansion of T cells or B cells by controlling factors such as total number and 
density of the haptens grafted along the polymer. (7, 9, 11)   
More recent in vitro analysis of these “rules” has yielded slightly different results.  In cell 
culture comprised of specific populations of target immune cells, larger therapeutic constructs 
with higher hapten density and stronger binding avidity often produced the largest cellular 
response. (12)  This conflicting data resulting from in vitro studies suggested that additional 
elements must factor into the immune response generated in vivo.  Deciphering these 
differences is complicated by the highly variable environment these polymeric nanomaterials 
experience when dosed by different routes.  There is a need for transport of the nanomaterials 
away from or immune cells to the site of injection before immune activation can be achieved.  
Synergizing these findings suggests that nanomaterials indeed dictate the immune response via 
multivalent presentation of antigen, but also control the transport and localization in vivo to tailor 
immune response. 
 
1.2 Peripheral Delivery and Inflammatory Response: Vaccines 
Vaccines rely on the recruitment of immune cells to the site of injection to generate an 
effective immune response. (13-15) Professional antigen presenting cells (pAPCs) such as 
dendritic cells (DCs) must be recruited to the periphery, sample from the microenvironment, 
then migrate to the lymphatics where they may activate naïve lymphocytes. (16)  The use of 
adjuvants or immunogenic vaccine particles can enhance recruitment, recognition, and uptake 
of the injected material by pAPCs. (4, 13)  After uptake and processing of the vaccine antigen, 
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activation of the innate immune response further enhances recruitment of immune cells to the 
injection site (Figure 1). (13, 17-19)   
Figure 1: Activation of specific cellular immune responses. 
 
Initial steps in immune activation include increased co stimulatory and antigen 
recognition capacities.  Specifically, the surface density of cellular receptors such as cell-
adhesion molecules and the major histocompatibility complex (MHC) is increased.  The main 
functions of this up-regulation are to enhance recognition of pathogenic antigens and to prime 
CD4+ and CD8+ T cells to help initiate the adaptive immune response.  After clonal expansion of 
T cell populations, interaction between T and B cells leads to B cell activation, expansion, and 
conversion to plasma cells responsible for antibody secretion.  The circulating antibodies 
produced aid in the clearance of the detected pathogen.  Direct interaction of activated DCs with 
CD8+ T cells converts these T cells to cytotoxic lymphocytes (CTLs) and induces the secretion 
of signaling factors to down-regulate immunosuppressive CD25+ regulatory T cells (Treg).  
Adaptive immune cells differentiate into memory cells that prime the immune system in the 
event of a secondary exposure, thereby completing the immune response. (17-18, 20-21)    
These steps encompass rudimentary fundamentals of the immune response.  Multiple 
targets are available for therapeutics along these different arms.  Research continues to explore 
adaptive priming as with vaccines and new trends in cancer therapy often aim to induce a 
selective pro inflammatory response (e.g. Th2).  Induction of a tolerogenic immune response 
has also gained momentum; for example, Treg production is desired in the case of autoimmunity 
where the body fails to differentiate self from non-self.   
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1.3 Antigen Presentation and Immune Response: “Dintzis’ Rules” 
One of the key steps of immune activation is the presentation of antigen on the surface 
of pAPCs.  After intracellular processing, the antigen is typically presented on the pAPC surface 
bound in the cleft of MHCs.  Next, MHCs position themselves on the cellular surface with 
defined spacing and present the antigen with a specific orientation. (22)  These spacing 
densities and antigen orientations help dictate the type of T cell (Th1 or Th2) or B cell response.  
While the antigen-MHC complex is difficult to recreate synthetically, nanomaterials can be 
constructed to emulate some of the antigen presentation characteristics. 
 Immune response can be maximized by recognizing distinct guidelines for recognition, 
processing, and clearance.  Generally, materials with a Mw greater than 100 kDa and/or particle 
size of 50-5000 nm can be efficiently recognized and processed by dendritic cells and other 
pAPCs. (23-25)  In addition to the initial recognition event, physical properties of the material will 
determine whether it is digested and/or cleared from the system and whether an immune 
response will be activated. (15)  Similar to vaccines using adjuvants with adsorbed antigen, 
immune response to nanoparticles is dependent on the antigen type and display characteristics. 
(17-19)  The number, density, and spacing of antigen plays an essential role in directing the 
immune response.   
The importance of antigen display is perhaps best outlined in the work completed by 
Dintzis and others beginning in the late 1970’s. (10, 26)  “Haptens” (both small molecule and 
small peptide antigens) were systematically grafted (varying number and density) to polymers of 
discrete Mw.  These antigen arrays were administered to animals IP, and the T cell or B cell 
responses were measured through cytokine or antibody production to characterize the immune 
response. (6-9, 11, 27-28)   Hapten valance was critical to illicit an immune response, with 
materials displaying less than 10 haptens no longer generating a response.  The immune 
response appeared to be driven by the hapten characteristics along the polymer backbone and 
6 
 
further investigation also suggested that there were critical spacing and density parameters to 
illicit specific cellular responses, independent of polymer Mw (Table 1).   
Table 1: Material characteristics that produced the specified cellular response. 
Effected 
Cells 
Polymer 
Scaffold 
Mw (Da) 
Total 
Estimated 
Haptens 
Hapten 
per 
1000 Da 
T Cells 
100,000 20 5 
30,000 7 4.3 
600,000 – 
2,000,000 300 - 600 3.5 - 5 
B Cells 
(Anti-TM Ab) 
 
3,000 2 1.5 
14,000 7 2 
63,700 36 1.76 
 
 
Much like the conserved sequences of pathogens that are recognized by pattern 
recognition receptors (PRRs), “Dintzis’ Rules” defined characteristics of soluble polymer 
constructs necessary for directing immune response: 
• Valency of haptens: must be >10 
• Spacing of haptens: 5-10 nm (50-100 Å) 
• Rigidity of haptens: immobilization of receptor 
• Binding kinetics and affinity 
The results of work by Dintzis and others provided convincing evidence that nanomaterials can 
be synthesized to generate a specific immune response.  We suspected that these findings also 
indirectly pointed to the role that transport plays in the immune response.  Nanomaterial 
solubility, flexibility, and size all affect the ability of nanomaterials to either reside at or drain 
from the injection site.  Additionally, location dictates the immune cell populations that the 
nanomaterials encounter.   
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1.4 Transport of Nanomaterials  
 The injection site plays a vital role in determining nanomaterial transport and final 
deposition site, which are important determinants of immune response.  The three major 
parenteral administration routes are intravenous (IV), intramuscular (IM), and subcutaneous 
(SC).  Each of these routes exposes the delivered nanomaterial to different initial and drainage 
environments. (29-30)  While IV injection provides immediate systemic exposure; both IM and 
SC administration require the material to drain away from the injection site before entering into 
systemic or lymphatic circulation.  Consequently, the nanomaterial properties and the local 
environment will determine the drainage kinetics from the injection site and the potential for 
retention at the injection site or accumulation in the lymph or blood pool. 
 Intravenous administration provides the optimal delivery route to give a dose quickly into 
systemic circulation.  Distribution is rapid, however, IV injection immediately exposes materials 
to circulating lymphocytes, digestive enzymes, and proteins found in the blood as well as first 
pass metabolism, which can lead to rapid clearance.  Materials below ~65 kDa or ~10 nm will 
show rapid renal clearance while larger materials may proceed to the spleen. (31)  The spleen 
serves as an immunologic filter for the blood.  Comprised of dendritic cells, natural killer cells, 
macrophages, B cells, T cells and red blood cells, the spleen captures foreign materials (e.g. 
antigens) from the blood.  Additionally, circulating lymphocytes capture foreign materials and 
bring them to the spleen for presentation to T and B cells.  Exposure to enzymes, renal and 
splenic clearance, antibody clearance, and other clearance mechanisms may make IV an 
undesirable choice for delivery of therapeutics that modulate immune response.  
Delivery of nanomaterials via IM injection is preferred over SC in cases where large 
volumes of a drug product are required.  The vaccine or therapeutic is usually injected into the 
upper arm, thigh, or buttock where the muscle is dense.  The major factor in drug absorption 
after IM injection is the relative blood supply to the muscle where decreased blood supply 
extends the absorption time.  Additionally, systemic exposure is often achieved only after the 
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materials pass through the draining lymph nodes. (32)  In particular, the lymph readily takes up 
high molecular weight complexes, particles, and macromolecules, while smaller materials (e.g. 
< 10 nm) are more likely to be transported directly to the blood. (33-34)  Drug can reside at the 
injection site for prolonged periods of time if the drug is large or partially immobilized (e.g. 
adsorbed on an adjuvant).  As a result, the extended residence time may favor a peripheral 
immune response mediated by DC and macrophage migration to the site of injection. 
Subcutaneous delivery is achieved through injection of the nanomaterials into fatty 
tissue just beneath the skin.  The subcutaneous space allows drainage away from the injection 
site depending on the relative size of the therapeutic or “carrier.”  Nanomaterials most likely will 
have one of three fates: 1) smaller materials (<10 nm) tend to drain to capillaries and into 
systemic circulation, 2) larger materials favor drainage into local lymphatic circulation and to 
secondary lymphoid organs, or 3) materials > 70 nm typically will remain at the injection site. 
(35-37) Therefore, immune modulating nanomaterials can be manufactured to take advantage 
of the subcutaneous drainage profile to provide optimal exposure to lymphatics and to minimize 
systemic exposure or peripheral immune response. 
 
1.5 Lymphatic Delivery and Tolerant Response: Immune Therapy 
 The lymph nodes provide various immunological environments with specific cellular 
populations sequestered in different compartments.  Within secondary lymphoid organs (e.g. 
lymph nodes and spleen), a very highly structured architecture exists that provides efficient 
induction of an immune response. (38-39)  This microenvironment in lymph nodes can be 
characterized into three distinct subunits: (1) an antigen sampling compartment rich in pAPCs 
that process and present antigens to (2) T cells within the paracortex or (3) B cells in the lymph 
node cortex containing B cell follicles.  This high level of organization helps to enhance cell-cell 
signaling and increases the probability of pAPCs encountering immune cells and antigen by 
bringing these populations together in a small volume environment. (38)  Immune response is 
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driven in part by cell interactions within the lymph nodes which can induce responses through 
clonal expansion of cytokine-producing and cytotoxic T cells as well as through production of 
high-affinity antibodies. (40)  The high concentration of immune cells as well as the efficient 
induction of immune response makes intra-lymphatic immunization very attractive for cancer 
vaccines. (41-44)  In addition, direct injection of allergens into the lymph nodes has successfully 
induced tolerance toward specific allergens. (39)  Traditional methods to promote tolerance 
toward specific allergens required multiple SC injections of the same allergen at low 
concentration over the course of years.  Recent clinical trials have demonstrated that delivery of 
the allergen directly into the lymph nodes resulted in rapid tolerization toward the allergen. (39-
40, 45-46)  
While the therapeutic applications appear to vary greatly, each tolerization strategy looks 
to take advantage of initiating an immune response by delivering extremely small amounts of 
“antigenic” material.  Promising results in the clinic suggest that delivery of materials into the 
lymph nodes whether through direct injection or drainage provides rapid exposure to a high 
concentration of immune cells.   This can elicit a quick and/or large immune response toward 
the delivered materials.  In many cases, the immune response can be directed toward antigen 
tolerance and not stimulation, a characteristic that is highly desirable in treating autoimmune 
diseases. 
 
1.6 Synergizing recent in vitro studies with “Dintzis’ Rules” 
The work of Dintzis provides strong and convincing evidence that antigen arrays can 
provide selective immune stimulation, however, as these “rules” were analyzed in vitro there 
appeared to be a deviation from in vivo results.  The work of Kiessling and others aimed to 
correlate in vivo activities of multivalent antigens seen by Dintzis, with affects on B cell receptor 
(BCR) localization and signal transduction in B cells. (47)  The studies focused on the ability of 
antigen arrays of large (500 haptens) and small (10 haptens) valencies to cluster surface 
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receptors and initiate an antibody response.  The in vitro data did not support the claims made 
by Dintzis and Kiessling argued that it was the ability to cluster BCRs that was critical in signal 
amplification and antibody production.  When tested, both the 500 hapten and 10 hapten arrays 
led to a high degree of BCR clustering (Figure 2), however, the resultant antibody production 
differed between the two populations. 
 
Figure 2: Visualization of BCR and glycosphingolipids localization on cell surfaces treated with 
multivalent ligands. BCR (purple) and glycosphingolipids (green) were overlayed and showed a high level 
of co-localization for both 10- and 500-hapten arrays. (47) Reproduced with permission. 
In a different study, Chittasupho and others used primary DCs primed with ovalbumin 
antigen to analyze the ability of nanoparticles displaying multiple copies of inhibitors of 
intracellular adhesion molecule-1 (ICAM-1) or lymphocyte function-associated antigen (LFA-1) 
to block binding of T cells to DCs.  The presentation of cell-adhesion ligands as multivalent 
arrays on the nanoparticle surface was hypothesized to enhance binding avidity and trigger 
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endocytosis of receptors, thereby blocking DC receptors and altering response better than free 
inhibitors.  Molecular staining of ICAM-1 and LFA-1 demonstrated each receptor was expressed 
on the surface of DCs.  Pretreatment of DCs with nanoparticle arrays (targeting either ICAM-1 of 
LFA-1) showed a >75% decrease in T cell conjugate formation with DCs compared to no 
treatment.  Similar to the work of Kiessling, the effect of receptor binding and clustering on cell 
proliferation and cytokine response was measured.  Although binding of DCs and T cells was 
inhibited to a similar extent by NPs displaying LABL or IBR, the resulting effect of the binding 
events was vastly different.  Compared to controls, T cell proliferation was arrested when T cells 
were incubated in the presence of DCs treated with LABL-NPs (targeting ICAM-1), whereas 
DCs treated with IBR-NPs (targeting LFA-1) dramatically stimulated T cell proliferation. 
Similarly, the cytokine profiles differed greatly for LABL-NPs compared to IBR-NPs with regards 
to the amount of IL-6 or IL-17 varying depending on NP type.  
These in vitro studies showed differing results in regards to cell surface receptor 
clustering and immune response for B cells (Kiessling and others) and T cells (Chittasupho and 
others).  In Kiessling’s model, BCR clustering was similar with treatment using different Mws of 
antigen arrays; however, each treatment produced different antibody production.  Similarly, 
Chittasupho and others observed NPs displaying different cell-adhesion inhibitors produced 
equal amounts of binding and cellular uptake with drastically different cell proliferation and 
cytokine responses.  These studies provide a look into how multivalent materials are interacting 
on the molecular and cellular level for specific immune cell subpopulations, but they are 
conducted on homogenous populations of immune cells ex vivo.  A potential explanation for the 
observed disagreement with Dintzis’ in vivo observations is that in vitro analysis provides the 
opportunity for all the tested materials to interact with the target cells.  When delivered in vivo, 
the larger materials will most likely remain at the site of injection and not drain to the nodes 
where naïve T and B cells reside.  Even so, the individual subpopulation differences provide 
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insight into what may be achieved if these nanomaterials are efficiently delivered to specific B or 
T cell populations in vivo.   
 
2.1 Introduction of thesis 
A specific cellular immune response can be achieved by particle or polymer 
nanomaterials displaying multiple copies of an antigen.  The factors directly responsible for the 
response are still a matter of contention.  In vitro studies provide an argument that the clustering 
event of cellular receptors and formation of an immunological synapse are essential in activating 
a potent cellular response.  Studies with allergen tolerization therapies, however, have shown 
that it is not only necessary for the body to recognize the immunogenic material, but also where 
the material is recognized is key to rapid tolerance induction.  Nanomaterials provide a unique 
scaffold that can be synthesized to address both molecular presentation motifs as well as Mw 
cutoffs to promote localization of the materials in lymph nodes.  The arrays investigated by 
Dintzis, Kiessling, and Chittasupho displayed a single hapten along the manufactured 
nanomaterial.  Research into enhancing the potency of T cell activation demonstrates that 
multiple signals and the number (valency), pattern, and translocation of these signals are direct 
contributors to the strength and type of immune response.  (48-49)  Nanomaterials that present 
antigen accompanied by a co stimulatory signal or cell-adhesion inhibitor provide yet another 
treatment strategy for traditional vaccines or tolerization therapy.  
 
2.2 BPI vs. Polymer based SAgA 
 Previous research demonstrated that fusion of a cell-adhesion antagonist and disease-
specific antigen in the form of a “bi-functional peptide inhibitor” (BPI) suppressed autoimmune 
disease in multiple models, including experimental autoimmune encephalomyelitis (EAE). (50-
53)  Efficacy of the BPI is proposed to be achieved through the ability of the inhibitor to disrupt 
the formation of the immunological synapse and, therefore, prohibit the activation or clonal 
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expansion of specific immune cell populations.   Its small size (~3000 kDa) would theoretically 
result is a large systemic concentration after SC injection due to rapid  absorption into the blood, 
unless the BPI binds to receptors at or near the injection site.  Systemic exposure may result in 
accumulation in the spleen where the immune cell population would vary greatly when 
compared to lymphatics that drain the disease site.   
Our research looked to build upon the success of BPI by expanding this construct to a 
polymer chain to create a “soluble antigen array” (SAgA).  The SAgAs were designed to take 
advantage of “Dintzis Rules” for hapten spacing and density to maximize the immune response 
against the disease antigen.  SAgAs were synthesized to simultaneously display peptides that 
inhibit the binding of ICAM-1 (LABL), or LFA-1 (IBR) alongside the EAE peptide antigen derived 
from proteolipid protein (PLP).  Both hyaluronic acid (HA) and PLGA nanoparticles were 
evaluated as scaffolds to display the peptides, which were covalently grafted to HA via a novel 
N-oxime chemistry.  In addition to antigen and cell-adhesion display, SAgA size was designed 
to promote local lymphatic drainage after SC injection, thus minimizing systemic exposure or 
retention at the injection site. (34-36)   
Targeting the lymphatics provides SAgAs the optimum ability to influence immune 
response.  SAgAs were, therefore, designed to promote rapid uptake into the local lymphatic 
structures and to extend the residence time within these structures.  Previous results by Forrest 
and others, demonstrated that hyaluronic acid showed lymphatic uptake and increased the 
efficacy of the grafted therapeutics, while decreasing systemic exposure and toxicity. (54-55)  
Unpublished results from the Forrest lab by Meyer and others, also demonstrated that a linear 
relationship between size and drainage kinetics did not exist, rather there was an optimum Mw 
(~75 kDa) of HA to achieve rapid drainage into lymphatic circulation and avoid systemic 
exposure after SC injection.  An outline of the design characteristics for SAgAs and rationale is 
shown in Table 2. 
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Table 2:  Target characteristics and rationale for the design of SAgAs. 
Structural Element Rationale 
Molecular Signaling Presentation of antigen and cell-adhesion inhibitor simultaneously, increases the suppression ability of the therapeutic 
Antigen Array Optimize the hapten number and density along nanomaterial to increase ability to interact with cell surface receptors 
Size Control drainage characteristics to promote lymphatic drainage and increase interaction with target immune cells 
  
 
2.2.1 Design of Thesis 
 The work outlined in this thesis encompasses the synthesis, physical characterization, 
and in vivo testing of SAgAs developed to treat EAE, the murine model of multiple sclerosis 
(MS).  These arrays were synthesized using a soluble hyaluronic acid polymer backbone or 
PLGA-NP scaffolds.  An antigen peptide (PLP) and/or cell-adhesion inhibitor (LABL or IBR) 
were conjugated to each of these scaffolds.  The resulting conjugates were characterized and 
then tested in vivo in the EAE mouse model to establish efficacy.  Later studies focused on the 
effect of cell-adhesion target (ICAM-1 or LFA-1) and therapeutic size on the ability of the 
materials to suppress EAE, alter the drainage away from the point of injection, and induce 
specific cytokine responses.   
Chapter 2: Synthesis and characterization of SAgAs 
  Peptides were conjugated to the HA scaffolds via novel N-oxime chemistry.  This 
conjugation scheme eliminates the need for modification of reactants, harsh reaction conditions, 
and/or multi-step reactions.  The N-oxime reaction pathway was validated through extensive 
studies of reaction product using mass spectroscopy, nuclear magnetic resonance 
spectroscopy, and Fourier transform infrared spectroscopy.  After the chemistry was validated, 
SAgAs were synthesized and the relative Mw, peptide concentration, and reaction efficiency 
were calculated using analytical techniques such as Gel Permeation Chromatography and High 
Pressure Liquid Chromatography.   
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Chapter 3: Evaluation of SAgA efficacy and effect of SAgA scaffold 
 SAgAs were synthesized to display a cell-adhesion inhibitor (LABL) and antigen (PLP) 
peptides by conjugating the peptides to hyaluronic acid or PLGA-NPs.  After characterization, 
the materials were injected SC into mice with EAE.  All manufactured arrays were compared 
against a negative PBS and positive PLP-BPI control.  Therapeutic efficacy was evaluated by 
measuring clinical score and body weight over 25 days.  Further studies evaluated the effect of 
increasing dose and inhibitor type for comparison to controls including, LABL (cell-adhesion 
inhibitor) only, PLP (antigen) only, free LABL + PLP peptides, or free scaffold (HA vs. PLGA-
NP). 
 Chapter 4: Optimization of SAgAs – Effect of target and size 
 To further optimize EAE suppression, SAgAs displaying an alternate cell-adhesion 
inhibitor (IBR) were synthesized.  Additionally, SAgAs with lower Mw were synthesized to 
enhance drainage of the materials to the lymphatics.  Clinical scores and body weight in the 
EAE mouse model were evaluated, and in vivo imaging of SAgAs and cytokine analyses were 
conducted.  In vivo imaging was used to qualitatively track retention or drainage of SAgAs from 
the injection site.  The circulating concentration of pro inflammatory (IFN-γ, TNF-α, and IL-2) 
and anti-inflammatory or tolerogenic (IL-4, IL-10, and IL-17) cytokines provided insight into the 
underlying immunological mechanisms of the immune responses. 
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Chapter 2 
Synthesis and characterization of SAgAs 
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2.1 Introduction 
Oxime chemistry has emerged as a promising conjugation scheme that utilizes the high-
ly specific reaction of aminooxy groups to aldehydes or ketones. (1-4)  The reaction can be car-
ried out in water and avoids harsh catalysts or reaction conditions. (5)  In addition, aminooxy 
reactivity is significantly higher than primary amines, thus conferring the desired specificity for 
conjugation using polypeptides. (3, 6-7)  One drawback to this approach has been the need for 
an aldehyde or ketone group to provide a reactive site.  A characteristic that usually necessi-
tates engineering the reactant.   
Currently, synthetic glycoconjugation would benefit from simplified reaction schemes. (6)  
Polysaccharides and peptides cannot be exposed to many of the conditions required for tradi-
tional conjugation schemes (e.g. solvent, pH, temperature) due to stability concerns. (8)  In ad-
dition, current approaches often utilize multiple steps, such as activation procedures to form 
reactive intermediates or the addition of linker molecules to facilitate stability or to improve reac-
tion efficiency. (9)  These encumbrances coupled with low product yields and lengthy purifica-
tion procedures make many of the current glycoconjugation methods inconvenient for transla-
tional medicine or assays and impractical for scale-up. (9-10)   
An additional roadblock in the synthesis of glycoconjugates is the inefficiency or variabili-
ty of reactions.  Research efforts may halt at the bench due to low reactivity, the need for cata-
lysts, complex addition of reactive sites, and/or the use of undesirable solvents.  Further prob-
lems emerge when conjugating multiple peptide species since small differences in reactivity 
may yield unpredictable molar ratios. (11)  Such issues inhibit the exploration of multivalent or 
multifunctional polymers or colloids with defined ligand densities and ratios.   
Oxime chemistry has historically focused on aldehyde or ketone reactions to aminooxy 
groups. (9)  Here, aminooxy reactivity to the carbonyl carbon on N-acetyl amides was investi-
gated as a unique approach to synthetic glycoconjugation.  Specifically, N-acetyl glucosamine 
(NAG) was explored as a link to glycosylation or functionalization of glycosaminoglycans such 
as hyaluronic acid. (12-13)   
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2.2 Materials 
N-acetyl glucosamine, glucuronic acid, N-vinyl formamide, research grade sodium ace-
tate, acetic acid, O-(carboxymethyl) hydroxylamine hemihydrochloride (OCMH), and D2O were 
purchased from Sigma.  Hyaluronic acid, with an average molecular weight of 31 kD was pur-
chased from Lifecore.  Amino acids were purchased from Peptides International.  Analytical 
grade acetonitrile and synthesis grade trifluoro acetic acid (TFA) were purchased from Fisher 
Scientific. Peptides and poly-N-vinyl formamide (PNVF) were synthesized by the laboratory.  
Water was provided by a Labconco Water PRO PS ultrapure water purification unit.   
 
2.3 Methods 
Peptide Synthesis.  Aminooxy peptides were synthesized using 9-fluorenylmethyloxycarbonyl-
protected amino acid chemistry on polyethylene glycol-polystyrene resins.  The peptides syn-
thesized were aminooxy-LABL (aminooxy-ITDGEATDSG, Ao-LABL), a cell-adhesion molecule 
antagonist,(14) and aminooxy-proteolipid peptide (PLP) (aminooxy–HSLGKWLGHPDKF, Ao-
PLP), a known antigen epitope in multiple sclerosis.  Peptides were deprotected, cleaved from 
resin, and isolated by precipitation in ether. Purification was completed using preparatory high 
performance liquid chromatography (HPLC) followed by lyophilization.  Peptide purity was as-
sessed using analytical HPLC and the identity of the synthesized peptide was confirmed by 
electrospray ionization mass spectrometry. 
Reaction of Aminooxy Molecules to Monomer/Polymer.  The reaction conditions were iden-
tical for all monomers and polymers used (N-acetyl glucosamine, glucuronic acid, PNVF and 
hyaluronic acid). The aminooxy-containing small molecule OCMH and peptide species were 
both tested.  For small molecule monomers, 45 μmol NAG (Mw 221, 10.07 mg) was mixed with 
45 μmol OCMH (Mw 109, 4.97 mg) in 5 mL acetate buffered (20 mM) saline solution pH 5.5.  
After addition of all reactive species the pH was measured and adjusted to 5.5 ± 0.1.  For poly-
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mers and peptide reactions, 1.3 μMol polymer was dissolved into 20 mM acetate buffered saline 
(pH 5.5 ± 0.1).  Once dissolved, 1.3 μMol aminooxy-peptide was added to the solution.  When 
more than one peptide species was added, 0.65 μMol of each peptide was weighed out sepa-
rately then both were added simultaneously.  After addition of the aminooxy species, the reac-
tion solution pH was adjusted to pH 5.5 ± 0.1.  The solution was mixed for 16 hr at room tem-
perature.  After 16 hrs the samples were frozen at -70 °C and lyophilized.  For kinetic experi-
ments, samples were taken from the reaction vessel at predetermined time points and analyzed 
immediately.  For peptide conjugates the reaction products were purified by dialysis to remove 
excess free peptide, and lyophilized.  Exact procedure for reaction can be found in supplemen-
tal materials. 
Mass Spectroscopy.  Masses of conjugates and of synthesized peptides were determined by 
electrospray ionization mass spectroscopy by using a waters LCT premier ESI mass spectrome-
ter running MassLynx software. 
Fourier Transform Infrared Spectroscopy. Changes in bonding environments during reaction 
were monitored using a Bruker Tensor 27 FTIR spectrometer equipped with a ZnSe attenuated 
total reflectance (ATR) plate (Pike Technologies).  Fourier transform infrared (FTIR) spectra 
were collected at room temperature (25 °C). Data were collected over 256 composite scans with 
a resolution of 4 cm-1. The samples were analyzed in 20 mM acetate buffered saline at a con-
centration of 3 mg/mL. Spectra from OCMH in solution were subtracted using the OPUS spec-
troscopy software and data were further analyzed using GRAMS/AI (Galactic, Inc.).   
Nuclear Magnetic Resonance Spectroscopy.  For structural analysis of the various mono-
mers and conjugates, samples were dissolved in D2O to a concentration of 10 mg/mL.  H1 and 
C13 spectra were acquired on a Bruker 400MHz spectrometer at 25 °C. 
Gel Permeation Chromatography.  The change in molecular weight of hyaluronic acid conju-
gates was determined using a Viscotek GPC max VE 2001 GPC solvent/sample module, VE 
3580 refractive index detector, and 270 Dual Detector with right angle light scattering.  Samples 
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were separated by utilizing a tandem column setup of two Viscogel, GMPWxl grade, columns 
(Viscotek) at a flow rate of 1 ml/min and isocratic elution in water for 30 min. 
High Performance Liquid Chromatography. Peptide was quantified by gradient reversed-
phase HPLC (SHIMADZU) using a Vydac HPLC protein and peptide C18 column. The HPLC 
consisted of a SCL-20A SHIMADZU system controller, LC-10AT VP SHIMADZU liquid chroma-
tograph, SIL-10A XL SHIMADZU auto-injector set at 75 μL injection volume, DGU-14A 
SHIMADZU degasser, sample cooler, and SPD-10A SHIMADZU UV-vis detector (220 nm). The 
HPLC-UV system was controlled by a personal computer equipped with SHIMADZU class VP 
Software. Gradient elution was carried out at constant flow of 1 mL/min, from 100% A to 35% A 
(corresponding to 0% B to 65% B) for 50 min, followed by an isocratic elution at 75% B for 3 
min. Mobile phase compositions were (A) acetonitrile-water (5:95) with 0.1% TFA and (B) ace-
tonitrile-water 90:10, v/v) with 0.1% TFA.  At the end of each analysis, the cartridge was re-
equilibrated at initial conditions at 1 mL/min flow rate for 5 min with A.  
 
2.4 Results and Discussion 
Aminooxy chemistry presents an opportunity for glycoconjugation in a specific manner 
due to the preferential reactivity of the amino ester for certain carbonyl carbons. (2)  Aminooxy 
reactivity to aldehydes and ketones is well known, (1, 3, 15-16) but reactivity to free amides 
(e.g. N-acetyl or N-formyl) has yet to be explored.  It has been previously reported that hyalu-
ronic acid (HA) modification with aldehydes confers aminooxy reactivity; (1, 6) however, the po-
tential to react directly to unmodified  N-acetyl sites on HA or other glycosaminoglycans (GAG) 
would have far reaching implications.  In addition, conjugation to GAGs or inversely, the synthet-
ic glycosylation of polypeptides, typically requires complicated reaction schemes.  A single-step, 
aqueous glycoconjugation strategy would be useful. 
Using O-(carboxymethyl) hydroxylamine (OCMH), the potential for an aminooxy reaction 
to the monomers of HA, glucuronic acid (GLU) and N-acetyl glucosamine (NAG), was probed.  
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Both of these groups display a carbonyl carbon; a carboxylic acid on glucuronic acid and an 
amide on N-acetyl glucosamine (Figure 1).  Individual monomers were reacted with OCMH in an 
acetate buffered saline and the product was analyzed by mass spectroscopy.  The spectrum for 
the reaction product between GLU and OCMH (Figure 2) showed the presence of the GLU (Mw 
= 144.1) and OCMH (Mw = 91), however, no reaction product was present.  In the mass spectra 
for the reaction between NAG and OCMH, a peak at a mass of 317 Da was found in addition to 
the reactants themselves (Figure 3).  This molecular mass was equivalent to the theoretical 
mass expected for aminooxy conjugation through the N-acetyl site of NAG, thus supporting the 
possibility of an N-oxime reaction scheme.  It should be noted that in both mass spectra for GLU 
and NAG, there is a peak at 286 for GLU and at 285 for NAG in the stock material that also ap-
pears in the final product. 
With the mass spectroscopy data suggesting a reaction was occurring, the products 
were analyzed to identify the groups involved in the reaction process.  The NAG + OCMH prod-
uct was analyzed by H1 (Figure 4) and C13 (Figure 5) NMR.  The H1 NMR data showed the 
appearance of new environments at ~2 ppm as a result of the methyl hydrogens in the OCMH 
backbone, and at 6.5 and 7.5 ppm due to the appearance of the proposed N-oxime bonding en-
vironments.  The ring environment from 3-4 ppm shifted slightly, which could be due to interac-
tions between NAG and the new OCMH side groups.  C13 NMR was used to identify the ef-
fected carbons in the reaction.  The amide environment was indeed involved in the reaction as 
the amide carbon (~175 ppm) shifts to 150 ppm, indicative of the proposed N-oxime-bonded 
carbon. (17)  Additionally, the carboxylic acid environment of unreacted OCMH appeared in the 
product spectra at 180 ppm along with the methyl carbons in the backbone of OCMH at 25 ppm.  
The NMR data supported the notion that the N-acetyl amide groups do confer aminooxy reac-
tivity. 
In addition to the NMR data, changes in bonding environments of the reactants were 
monitored throughout the course of the reaction.  The experiment was conducted with the ami-
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nooxy-reactive molecule OCMH in 10-fold excess and any changes in either GLU or NAG were 
monitored using FTIR over a 24 hour reaction period.  For all FTIR spectra, the free OCMH in 
solution was subtracted resulting in the FTIR spectra showing only changes in NAG or GLU.  
When the reaction between GLU and OCMH was analyzed, the FTIR data showed no change in 
the bonding environment over the entire 24 hr period (Figure 6-A).  When the reaction of NAG 
and OCMH was analyzed (Figure 6-B), the amide bonding environments at 1650 and 1550 cm-1 
decreased throughout the course of the reaction.  In addition to the disappearance of the amide 
bonding environments, two new bonding environments appeared; the carboxylic acid environ-
ment due to the addition of OCMH to NAG at 1700 cm-1 and an expected N-oxime environment 
at 1250 cm-1.  Thus, mass spectroscopy, NMR, and FTIR data demonstrated that a reaction is 
occurring between the amide carbon of NAG and the aminooxy of OCMH.   
An additional control study was conducted to further evaluate aminooxy reactivity to free 
amides.  In this study, polyacrylic acid (only carboxylic acid side groups) and poly-N-vinyl for-
mamide (only N-formyl side groups) were probed for aminooxy reactivity.  Polyacrylic acid exhi-
bited no reactivity as expected (Supplementary Figure 1-A) while poly-N-vinyl formamide 
reacted with OCMH.  A time course analysis using FTIR showed a decrease in amide peak at 
1650 cm-1 and an increase in an N-oxime bond peak as the appearance of a shoulder at 1600 
cm-1 (Supplementary Figure 1-B).  
N-oxime chemistry was further probed by grafting an aminooxy reactive peptide to hyalu-
ronic acid (HA).  The peptides LABL and PLP were synthesized with a terminal aminooxy group 
to confer reactivity.  The peptide molecular weights were confirmed by mass spectroscopy 
(Supplementary Figure II-A and Supplementary Figure II-B) with a purity >90% as determined 
by HPLC.  In the first study, Ao-LABL was mixed with HA in acetate buffered saline.  For refer-
ence, the number of reactive sites per mole of HA was calculated by dividing the mean molecu-
lar weight of HA by the monomer unit molecular weight (Table 1).  After the designated reaction 
time, the product was extensively dialyzed to remove any unreacted free peptide.  The conju-
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gate product and the dialysate were lyophilized and the reaction efficiency was determined by 
reversed-phase HPLC.  The mass of unreacted peptide in the dialysate was compared to the 
mass of peptide conjugated to the HA.  Grafted Ao-LABL was hydrolyzed from the conjugate 
prior to analysis using buffer at pH 2 (Table 2).  A reaction efficiency of 64% was achieved at 8 
hours reaction time. By extending the reaction time from 8 hours to 16 hours and maintaining 
the buffer at 20 mM acetate, a reaction efficiency of ~90% was achieved (Table 2). 
In addition to analyzing the peptide concentration hydrolyzed from the HA, the change in 
size of the conjugate product was also analyzed by GPC and compared to different molecular 
weights of HA (Figure 7).  The conjugate product showed an increase in relative molecular 
weight as indicated by the shift to a smaller retention volume.  The peak width remained rela-
tively constant suggesting that the polydispersity of HA did not substantially change after conju-
gation. Thus, the peptide graft density may have been similar on each HA chain.    
Next, the simultaneous conjugation of two aminooxy-peptides was investigated.  Equal 
moles of Ao-LABL and Ao-PLP were added to HA and the reaction was carried out for 16 hours.  
After extensive purification by dialysis and lyophilization of the product, the peptides were 
cleaved from HA and analyzed by HPLC to determine the mole percent of each peptide on the 
HA backbone.  Both peptides were grafted to HA at nearly an equimolar ratio (Table 3).   
The stability of the N-oxime bond between the peptide and HA polymer was also investi-
gated by challenging the conjugate with different pH buffer conditions.  Previous studies involv-
ing oxime bonds resulting from the reaction of aminooxy groups with aldehydes or ketones have 
shown that the oxime bond is labile to both acid- and based-catalyzed hydrolysis.  The rate of 
hydrolysis was pH dependent at high and low pH; however, the rate becomes independent of 
pH between pH 5-8. (18-19)  The stability of the synthesized HA-peptide conjugates was eva-
luated across a pH range of 2 – 7.5 by putting the dissolved conjugate into three different pH 
buffer conditions and measuring the peptide released into solution.  The released peptide hy-
drolyzed from the HA backbone was quantified by HPLC over the course of 300 minutes.  Con-
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jugates at pH 5.5 and 7.5 reached an apparent equilibrium by 240 minutes with a total of 10% of 
peptide hydrolyzed from the conjugate.  At pH 2, 100% of the peptide was hydrolyzed after only 
60 minutes (Figure 8).   
 
2.5 Conclusions  
In this report, a single-step glycoconjugation in aqueous buffer was performed by react-
ing an aminooxy small molecule or peptide to the amide side chain of N-acetyl glucosamine or 
hyaluronic acid.  In addition to the conjugation of a single aminooxy reactive molecule, it was 
demonstrated that two different peptides could be conjugated to hyaluronic acid in an equimolar 
ratio.  This N-oxime chemistry establishes a simple and unique scheme for reacting available 
amides to aminooxy compounds, thus enabling simple strategies for glycoconjugation.  
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TABLES 
Table 1: Molar concentration of amide sites per mole of HA. 
Mean HA 
Mw (Da) 
Monomer 
unit Mw (Da) 
# amide sites 
per Mole of HA 
31,000 417 74.3* 
*Indicates the number of amide sites.  For reference, there are an equal number of carboxylic acid sites. 
 
Table 2: Mass balance of HA – Ao-LABL conjugate product as compared to standard control.   
Sample Area Under Curve 
Total Area 
of Peaks 
Ao-LABL Peptide 8799141 8799141 
HA conjugate (8 hr)* 5633361 
8774823 Dialysis Solution (8 
hr)** 3141462 
HA conjugate (16 hr)* 8421520 
8421520 Dialysis Solution (16 
hr)** Not detected 
*Peptide was first hydrolyzed from HA at pH 2 
**Unreacted peptide in dialysate 
 
 
Table 3: HPLC analysis of dual-peptide conjugate. 
Peptide Concentration (nMol) mol % 
Ao-LABL 650 54 
Ao-PLP 550 46 
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FIGURES 
 
Figure 1: Structures of O-(carboxymethyl) hydroxylamine, glucuronic acid, and N-acetyl glucosamine  
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Figure 2:  (A) ESI+ mass spectroscopy of GLU stock material. (B) ESI+ mass spectroscopy of the unpuri-
fied mixture of glucuronic acid and OCMH showing the absence of any product peak.   
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Figure 3: (A) ESI+ mass spectroscopy of NAG stock material. (B) ESI+ mass spectroscopy of the unpuri-
fied reaction product between NAG and OCMH showing the product peak at 295 and product plus Na+ at 
317.   
 
32 
 
 
Figure 4:  H1 NMR spectrum showed expected changes from (A) NAG and (B) OCMH to (C) reaction 
product of NAG monomer with OCMH.  Product spectra showed the appearance of peaks at ~6.5 and 7.5 
ppm corresponding to the proposed N-oxime bonding environment. 
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Figure 5: C13 NMR spectrum showed expected changes from (A) NAG monomer and (B) OCMH to (C) 
reaction product of NAG monomer and OCMH.  The product spectra showed that the amide carbon peak 
(~175 ppm) shifted to ~150 ppm indicative of the proposed N-oxime bonding environment. 
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Figure 6: (A) FTIR spectra showed no change over time in glucuronic acid mixed with OCMH.  (B)  FTIR spectra 
showed changes in bonding environments for NAG reacted with OCMH.  The decrease in absorbance at 1650 
and 1550 cm-1 and the increase in absorbance at ~1750 and 1250 cm-1 over time are indicative of the loss of the 
amide environment and the appearance of carboxylic acid and proposed N-oxime environments due to the reac-
tion of NAG with OCMH. 
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Figure 7:  GPC refractive index chromatograms showed the increase in molecular weight as indicated by smaller 
retention volumes for hyaluronic acid with grafted Ao-peptides (circles) compared to 17 kD hyaluronic acid (trian-
gles) and 31 kD hyaluronic acid (squares). 
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Figure 8: The release of Ao-LABL peptide from hyaluronic acid by hydrolysis of the N-oxime bond at three pH 
conditions.   At pH 5.5 and 7.5, peptide concentration approached 10% after ~240 minutes while ~100% of the 
peptide was hydrolyzed from HA after 60 minutes at pH 2. 
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SCHEMES 
 
Scheme 1: The proposed reaction of aminooxy reactive OCMH with the amide of N-acetyl glucosamine. 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1:  (A) The FTIR spectra of a mixture of the PAA polymer (carboxylic acid side groups) 
with OCMH showed no change in bonding environments.  (B) The FTIR spectra of the reaction of PNVF (amide 
side groups) with OCMH showed a decrease in the amide peak at 1650 cm-1 and an increase in the N-oxime 
bond peak as the appearance of a shoulder at 1600 cm-1. 
 
Supplementary Figure 2: (A) ESI+ mass spectroscopy of purified Ao-LABL peptide with the expected mass of 
1038. (B) ESI+ mass spectroscopy of purified Ao-PLP peptide with the expected mass of 1594. 
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Chapter 3 
Evaluation of SAgA efficacy and effect of SAgA scaffold 
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3.1 Introduction 
 
Autoimmune diseases are often propagated through professional antigen presenting cells 
(pAPCs) stimulating the clonal expansion of T-cells recognizing endogenous antigen.  In the 
autoimmune disease multiple sclerosis (MS), activation of immune cells leads to attack on the 
central nervous system (CNS) resulting in neural degeneration.  The majority of FDA-approved 
therapies focus on suppressing disease symptoms through inhibition of the immune 
inflammatory response, despite substantial side effects. (1)  Newer therapies aim to return 
function after an attack, prevent new attacks, and prevent disability. (2)  These approaches are 
common among many autoimmune disorders such as diabetes, rheumatoid arthritis, lupus, and 
asthma, but, they typically fail to address the underlying pathogenesis. (3)  Therapies that 
specifically disarm the immune response induced by offending endogenous antigens are 
needed. 
In MS, new therapeutic strategies have recently emerged.  Clinical data for the monoclonal 
antibody (mAb) TYSABRI® revealed that blocking integrin α4β1 led to improvement in patients 
with MS. (4-7)  Immune suppression (8) and risk of multiple serious side effects, (9) however, 
are still a concern.  Ineffective disease treatment has led to a new class of “antigen-specific” 
therapeutics. (10)  An FDA-approved MS therapy that utilizes this approach, Copaxone®, 
employs polymeric antigen in an effort to promote tolerance by inducing regulatory T-cells. (11-
13)  Although clinical enthusiasm is somewhat dampened by adverse events and questionable 
long term effectiveness, Copaxone® demonstrates that this form of antigen delivery can 
improve clinical outcomes.   
Utilizing antigen to induce specific immune responses is not new.  Vaccines commonly use 
adjuvanted antigen presented as repeating patterns adsorbed on surfaces to induce immune 
protection. (14-17)  Alternatively, frequent low doses of soluble antigen have been used to 
induce tolerance.  In both cases, the formulation and dose regimen are customized and 
underlying mechanisms of action are typically complex.  Traditional formulations often focus on 
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the chemical induction of the immune response (e.g. adjuvanting to activate toll-like receptors).  
But, the physical context of antigen presentation is a critical driver of immune response as well. 
(18-19)   
Beginning in 1976, Dintzis and others systematically studied a wide range of polymers with 
grafted ‘haptens’ (e.g. antigens) and developed a set of rules for inducing immune stimulation or 
tolerance. (20-21)  This research demonstrated that, while molecular mass of the therapeutic 
did play an important role, the hapten valency was also critical in eliciting an immune response. 
Much like conserved sequences or patterns on pathogens that are recognized by the immune 
system, “Dintzis Rules” proposed that characteristics such as polymer size, solubility, and 
flexibility, as well as antigen valency, spacing and binding avidity are necessary to direct the 
immune response.   
Other research has focused on the chemical context of antigen recognition.  Surfaces 
displaying both grafted antigen and grafted cell-adhesion molecule achieve efficacy by 
interrupting the formation of the immunological synapse. (22-26)  A “bi-functional peptide 
inhibitor” (BPI) synthesized by the fusion of an MS epitope peptide, PLP, and a cell-adhesion 
molecule inhibitor peptide (LABL)  via a flexible linker of defined length has demonstrated 
efficacy in the EAE model. (27)  While the mechanism behind its efficacy has not been 
elucidated, previous research showed that by binding ICAM-1 one could block T-cell adhesion 
to intestinal epithelial cell monolayers. (28)  Building off of these results, BPI was designed to 
display antigen and cell-adhesion inhibitors simultaneously. These results led to the hypothesis 
that BPI could bind multiple cell signaling molecules simultaneously on the surface of the APC 
or T cells, thereby inhibiting immunological synapse formation.    
These findings plus Dintzis work prompted rational design of nanomaterials that display 
multiple copies of antigen and that simultaneously inhibit cell-adhesion.  Soluble Antigen Arrays 
(SAgAs) were synthesized by grafting a known MS antigen derived from proteolipid protein 
amino acids 139-151 (PLP) and, an ICAM-1 inhibitor (LABL) to hyaluronic acid (HA) via a novel 
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N-oxime chemistry (Chapter 2).  Once efficacy was demonstrated, the effect of dose was 
explored.  The physical properties (e.g. soluble HA polymer vs. PLGA nanoparticle) were also 
shown to play a vital role in efficacy.  Thus, these multivalent polymer therapeutics displaying 
cell-adhesion inhibitors and/or antigen were explored as potential therapeutics in treating 
experimental autoimmune encephalomyelitis.  
 
3.2 Materials and Methods 
Materials.  Hyaluronic acid (HA), with an average molecular weight of 31 kD was purchased 
from Lifecore.  Analytical grade acetonitrile and synthesis grade trifluoro acetic acid (TFA) were 
purchased from Fisher Scientific.  Research grade sodium acetate, acetic acid, and D2O were 
purchased from Sigma.  Water was provided by a Labconco Water PRO PS ultrapure water 
purification unit.  Poly (DL-lactic-co-glycolic acid) (50:50) (PLGA; inherent viscosity of 1.05 dL/g, 
Mw ~101 kDa) was purchased from LACTEL Absorbable Polymers International (Pelham, AL, 
USA). Pluronic® F68 (Mw ~8.4 kD) and Pluronic® F108 (Mw ~14.6 kD) were obtained from BASF 
Corporation. Acetone, diethyl ether and 1X Tris/EDTA buffer solution (pH 8) were obtained from 
Fisher Scientific. D-mannitol, Dess-Martin periodianine, tert-butyl carbazate (TBC), 
trinitrobenzenesulfonic acid (TNBS), dichloromethane anhydrous (DCM) and Triton X-100 were 
purchased from Sigma-Aldrich. 
Peptide Synthesis.  Aminooxy peptides were synthesized using 9-fluorenylmethyloxycarbonyl-
protected amino acid chemistry on polyethylene glycol-polystyrene resins.  The peptides 
synthesized were aminooxy-LABL (aminooxy-ITDGEATDSG, Ao-LABL), a ligand of ICAM-1 and 
aminooxy-PLP (aminooxy–HSLGKWLGHPDKF, Ao-PLP), an antigen derived from proteolipid 
protein amino acids 139-151 (PLP137-151).  Peptides were deprotected, cleaved from resin, and 
isolated by precipitation in ether. Purification was completed using preparatory High 
Performance Liquid Chromatography (HPLC) followed by lyophilization.  Peptide identity was 
verified and purity/content was assessed using Mass Spectroscopy and analytical HPLC.  BPI, 
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which is a fusion of PLP and LABL, was synthesized and purified as previously reported 
(HSLGKWLGHPDKF-AcGAcGAc-ITDGEATDSG).(29) 
Reaction of Aminooxy Peptides to Polymers.  HA was dissolved in 20 mM Acetate buffer (pH 
5.5 + 0.1 pH units) and aminooxy reactive peptide(s) added.  When both LABL and PLP 
peptides were used, each was weighed separately, and then added simultaneously.  After 
addition of the peptide(s), the reaction solution pH was adjusted back to pH 5.5 + 0.1 pH units.  
Reaction solutions were stirred at 500 RPM using magnetic stir bars for ~ 16 hr.  After the 
reaction, the soluble antigen array (SAgA) product was purified by extensive dialysis to remove 
any unreacted peptide, and then lyophilized. 
Gel Permeation Chromatography.  The relative molecular weight of the HA and of the SAgAs 
was estimated using a Viscotek GPC max VE 2001 GPC solvent/sample module, VE 3580 
refractive index detector, and 270 Dual Detector with right angle light scattering.  A tandem 
column setup of two Viscogel GMPWxl columns (Viscotek) was used at a flow rate of 1 mL/min 
with isocratic elution in water for 30 min. 
Conversion of terminal hydroxyl groups to terminal aldehyde groups on Pluronic® F108. 
To conjugate peptides to Pluronic® on PLGA nanoparticles an oxidizing reagent was used to 
convert hydroxyl groups on Pluronic®F108 (Pluronic®F108-OH) to aldehyde groups 
(Pluronic®F108-CHO). (30) One gram Pluronic®F108-OH was dissolved in 30 mL DCM. 
Subsequently, 58.1 mg Dess-Martin periodianine was added and reacted for 24 h at room 
temperature. The product was purified by precipitation in cold diethyl ether, followed by filtration. 
The obtained Pluronic®F108-CHO was verified by nuclear magnetic resonance spectroscopy 
(1H-NMR). Deuterated chloroform (CDCl3) was used to dissolve the samples. The conversion 
percentage was also determined. An excess amount of TBC was added to the Pluronic®F108-
CHO solution as previously described and the amount of unreacted TBC was measured using 
TNBS solution. A UV/VIS Spectrophotometer (SpectraMax) operating at 334 nm was employed 
to quantify the colored mixture of TBC and TNBS (30-32). 
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Preparation of PLGA nanoparticles.  A solvent displacement method was employed to 
prepare PLGA nanoparticles (NPs). (33-34) Briefly, PLGA (inherent viscosity 1.05 dL/g) was 
dissolved in acetone (15 mg/mL). A mixture of 1425 µL of PLGA solution and 75 µL 1X 
Tris/EDTA buffer solution was injected into 15 mL water containing 0.1% w/v Pluronic® using a 
syringe pump (10 mL/hr) while stirring (1000 rpm). Stirring was continued for 1.5 hours and then 
excess surfactant was removed by centrifugation (15,000 rpm, 15 min, 4°C) for 3 cycles, re-
suspending in water between cycles.  Using a sonication bath (Branson 2510 ultrasonic 
cleaner).  A 25:75 Pluronic® (CHO:OH) ratio was used for fabrication of NPs with conjugated 
PLP (NP-ArrayPLP), LABL (NP-ArrayLABL), or both (NP-ArrayLABL-PLP).  The 0:100 Pluronic® 
(CHO:OH) ratio was used as the control (NP-Blank) without any peptide conjugation.  
Conjugation of Peptides to PLGA nanoparticles.  Stock solutions of 2 mg/mL of PLP and 
LABL peptides were separately prepared. To prepare the NP-ArrayPLP, 4.0 mL of PLP stock was 
added to 102.3 mg NPs in 3.52 mL of water.  For NP-ArrayLABL preparation, 2.6 mL of LABL 
stock was added to 112.5 mg NPs in 3.2 mL of water.  Finally, to prepare the NP-ArrayLABL-PLP, 
3.6 mL of PLP stock and 2.34 mL of LABL stock were added to 227.84 mg NPs in 2.844 mL 
water.  The volume of each nanoparticle sample was increased to 50 mL using ddH2O. The 
volume of NP-Blank sample was also increased up to 50 mL as well (227.84 mg NPs). The 
samples reacted overnight and were purified by centrifugation (15,000 rpm, 15 min, 4°C) for 3 
cycles, resuspending in water between cycles.            
Dynamic Light Scattering.  Particle size was measured using a ZetaPALS dynamic light 
scattering instrument (Brookhaven Instrument Corporation).  
High Performance Liquid Chromatography. Quantification of free peptide post reaction was 
accomplished by gradient reversed phase HPLC (SHIMADZU) using a Vydac HPLC protein and 
peptide C18 column. HPLC system was composed of an SCL-20A SHIMADZU system 
controller, LC-10AT VP SHIMADZU liquid chromatograph, SIL-10A XL SHIMADZU auto-injector 
set at 75 μL injection volume, DGU-14A SHIMADZU degasser, sample cooler, and SPD-10A 
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SHIMADZU UV-vis detector (220 nm). A personal computer equipped with SHIMADZU class VP 
software controlled the HPLC-UV system. Gradient elution was conducted at constant flow of 1 
mL/min, from 100% A to 35% A (corresponding to 0% B to 65% B) over 50 min, followed by an 
isocratic elution at 75% B for 3 min. Mobile phase compositions were (A) acetonitrile-water 
(5:95) with 0.1% TFA and (B) acetonitrile-water (90:10, v/v) with 0.1% TFA. At the completion of 
each analysis, the cartridge was equilibrated at initial conditions at 1 mL/min flow rate for 5 min 
with A.  
Calculation of Peptide density on the surface of NPs.   Peptide surface density was 
calculated by subtracting the amount of peptide recovered after conjugation from the amount of 
peptide added to the NP suspension.  This value was then divided by the total surface area 
assuming a normal Gaussian particle size distribution and using a particle density of 1.34 g/cm3. 
NP-Blank suspension was used as a negative control. PLP and LABL at molar ratios of 100:0, 
50:50, and 0:100 were added to the NP-Blank and peptide adsorption was quantified as an 
additional control.  Peptide adsorption to blank particles or plastic was negligible.  
Induction of EAE and Therapeutic Study. SJL/J (H-2s) female mice, 4 – 6 weeks old, were 
purchased from The Jackson Laboratory and housed under specified, pathogen-free conditions 
at The University of Kansas. All protocols involving live mice were approved by the Institutional 
Animal Care and Use Committee.  Mice were immunized subcutaneously (s.c) with 200 μg of 
PLP139–151 in a 0.2 mL emulsion composed of equal volumes of phosphate-buffered saline (PBS) 
and complete Freund’s adjuvant (CFA) containing killed Mycobacterium tuberculosis strain 
H37RA (final concentration of 4 mg/mL; Difco). The PLP139–151/CFA was administered to regions 
above the shoulders and the flanks (total of four sites; 50 μL at each injection site). In addition, 
200 ng/100 μL of pertussis toxin (List Biological Laboratories Inc.) was injected intraperitoneally 
(i.p.) on the day of immunization (day 0) and 2 days post-immunization. The mice received s.c. 
injections of each sample, equivalent to 100 nMol PLP /100 μL, on days 4, 7, 10.  All NP 
samples were sonicated to disperse NPs before injection. For HA samples and controls, 100 μL 
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of each vehicle was injected.  For NP vehicles, 400 μL solution was used to assure suspension 
stability. Disease progression was evaluated blindly by the same observer using clinical scoring 
as follows: 0, no clinical signs of the disease; 1, tail weakness or limp tail; 2, paraparesis 
(weakness or incomplete paralysis of one or two hind limbs); 3, paraplegia (complete paralysis 
of two hind limbs); 4, paraplegia with forelimb weakness or paralysis; and 5, moribund (mice 
were euthanized if they were found to be moribund). Body weight was also measured daily. 
Statistical Analysis 
Statistical differences were determined by comparing treated groups to the negative control 
(PBS) for clinical disease score and body weight.  A one-way analysis of variance (ANOVA)  
followed by Fisher’s least significant difference was applied to these data. All analyses were 
performed using GraphPad Software (GraphPad Software Inc.). 
 
3.3 Results  
Characterization of polymeric Soluble Antigen Arrays.  Gel permeation chromatography 
(GPC) and HPLC were employed to observe any change in retention time resulting from the 
presence of peptides grafted to the HA.  When analyzed by GPC, the product showed a 
decrease in retention time suggesting an increase in molecular weight relative to the HA (Figure 
1).  To quantify the amount of peptide grafted to the polymer, the product retentate and 
dialysate (containing unreacted peptide) were analyzed by HPLC after extensive dialysis.  The 
product retentate was incubated at room temperature in pH 2 mobile phase buffer.  At this pH, 
the N-oxime bond is rapidly hydrolyzed, thus allowing quantification of the peptide released from 
the product.  Typical chromatograms showed the presence of the Ao-LABL peptide, the Ao-PLP 
peptide, or both (Figure 2-A).  The dialysate showed no peaks.  Any unreacted peptide was 
below the limit of detection of the HPLC (Figure 2-B).  A 1:1 ratio of the peptides was achieved.  
The apparent difference in peak intensities was primarily due to the different absorption 
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coefficients of these peptides.  Data for all the SAgA types suggested highly efficient grafting 
(Table 1).  
Conversion of terminal hydroxyl groups to terminal aldehyde groups on Pluronic® F108.  
The hydroxyl groups of Pluronic® were converted to aldehyde groups in order to utilize Pluronic® 
for conjugation to the terminal aminooxy of the PLP and LABL peptides. Pluronic® F108-CHO 
with aldehyde groups were prepared by the Dess-Martin oxidation reaction. To confirm 
conversion, 1H NMR spectra from before and after the reaction were compared. After 
conversion, the signal corresponding to the aldehyde group (δ=9.75) appeared which confirmed 
the conversion of hydroxyl groups to aldehyde groups (Supplementary Figure I). (30) The yield 
of the conversion was also determined to be 74.0% via a colorimetric TBC/TNBS assay. (31-32) 
Characterization of NP-Arrays.  Reversed phase HPLC was used to indirectly determine the 
amount of peptide conjugated to NPs.  NPs were centrifuged from solution and the amount of 
unreacted peptide was quantified from the supernatant.  Blank NPs and empty vials were used 
as controls to ensure that peptide was not being adsorbed to surfaces non-specifically.  The 
peptide density on the surface of NPs was calculated based on the total NP surface area, 
assuming a normal Gaussian particle size distribution (Table 2).  The NP-ArrayLABL-PLP had a 
1.1:1 ratio of LABL:PLP peptide on the surface.  Light scattering data showed that all NP-Arrays 
showed similar size both before and after peptides were conjugated to the surface (Table 2).  
For the nanoparticles displaying only one peptide, the NP-ArrayPLP had a similar surface density 
as the NP-ArrayLABL (Table 1).  The difference was not significant. 
Suppression of EAE by Arrays.  The SAgAs and NP-Arrays were evaluated in an EAE model 
induced in SJL/J mice.  The in vivo study designs are outlined in Table 3.  The disease onset 
usually occurs around day 8 and progresses to remission around day 20. Eight – 12 days after 
immunization, the mice showed disease signs, such as weakness, paralysis of their tail and 
limbs, and loss of body weight. Subcutaneous injections of each sample were given on days 4, 
7, 10. SAgALABL-PLP inhibited the progression of EAE more effectively (p<0.05, day 17) than the 
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28 kDa HA which was used as the SAgA backbone (Figure 3). The mice in the SAgALABL-PLP 
treatment group had very low clinical scores throughout the study (Figure 3-A) and scores were 
significantly lower (at the peak of the disease; days 11–17) than those of groups treated with 
PBS. The mice treated with SAgALABL-PLP also had significantly better maintenance of body 
weight (Figure 3-B) compared to the negative control PBS group (days 12 – 17).   In addition, 
50% of the mice receiving the SAgALABL-PLP treatment never developed EAE during the course of 
study.  Mice that showed few symptoms also exhibited a delay in disease onset (Figure 3-C). It 
should be noted that the HA polymer was administered at three times the molar concentration of 
HA in the SAgALABL-PLP.  Previously, a similar molecular weight of HA was shown to suppress 
disease by activating toll-like receptors or increasing Th2 response (35-37), thus some 
therapeutic efficacy was expected for HA.   
Once the efficacy of the SAgALABL-PLP was confirmed, the effect of SAgALABL-PLP dose was 
evaluated and compared to the positive control PLP-BPI.  The BPI molecule was composed of 
three portions: the EAE antigen peptide (PLP) and the ICAM-1 inhibitor (LABL) separated by a 
spacer (see methods).  Clinical results for BPI were consistent with previously published data. 
(27, 29, 38-39)  The effect of SAgALABL-PLP dose was evaluated by increasing the concentration 
to 200 nM and 400 nM as defined by the molar quantity of PLP antigen administered.  Clinical 
scores suggested that increasing the SAgALABL-PLP dose to 200 nM PLP reduced disease score 
(p<0.05, day 15, Figure 4-A). Further increasing the concentration to 400 nM PLP gave results 
similar to the 200 nM dose as no significant difference was seen between dose levels.  These 
results were corroborated by the weight loss in each treatment group, which showed similar 
trending (Figure 4-B).   
The role of scaffold was investigating by replacing the hyaluronic acid polymer backbone 
with a PLGA-Pluronic® nanoparticle.  The LABL and PLP peptides were grafted to the 
nanoparticles by reacting the aminooxy peptides to the particle surface.  These particles were 
then delivered as a suspension with the dose of PLP at 100 nMol.  The clinical scoring results 
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showed both the soluble polymer SAgALABL-PLP and colloidal NP-ArrayLABL-PLP provided disease 
suppression (Figure 5-A), however, the NP-ArrayLABL-PLP had a quicker onset and high incidence 
of disease when compared to the SAgALABL-PLP (Figure 5-C).   Animal weight data indicated that 
the SAgALABL-PLP and NP-ArrayLABL-PLP maintained animal body weight similarly throughout the 
study (Figure 5-B).   
The effect of multivalent display of only antigen or only the cell-adhesion inhibitor was also 
investigated by conjugating either PLP peptide or LABL peptide to the HA polymer or to the 
NPs.  As an additional control, a mix of free LABL and PLP peptides was tested.  Clinical scores 
suggested that the multivalent LABL treatments (SAgALABL and NP-ArrayLABL) exacerbated 
disease with data trending higher than that of the PBS control.  Conversely, the multivalent PLP 
treatments (SAgAPLP and NP-ArrayPLP) showed trending similar to or slightly lower than the PBS 
control (Figure 6-A).  Statistical analysis of these results, however, did not demonstrate 
statistical significance for either treatment.  The weight loss results corroborated scoring data for 
both the multivalent LABL and multivalent PLP treatments (Figure 6-B).  A mixture of free 
peptides (PLP and LABL) matched the PBS control indicating no clinical benefit (Figure 7).  An 
outline of all results and statistical significance compared to negative the PBS control are 
summarized in Table 4.   
 
3.4 Discussion 
In multiple sclerosis, destruction of myelin in the central nervous system is propagated by 
CD4+ T cells.  Activation of this subpopulation of T cells involves the formation of the 
immunological synapse at the interface between professional antigen presenting cells (pAPCs) 
and T cells.  Multiple therapeutic approaches aim to disrupt antigen recognition or immune cell 
adhesion as discrete strategies.  Modulation of immune response via peptide constructs has 
been the focus of much research in areas such as altered peptide ligands (APL), (40-43) 
splenocytes coupled with myelin basic protein (MBP)- or PLP- derived peptides, (44-45)  and a 
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soluble MHCPLP139–151 construct. (46)  The FDA-approved synthetic copolymer glatiramer 
acetate, marketed as Copaxone® contains four amino acids of MBP.  It is reported to generate 
a Th2 response and/or induce tolerance (Treg) as an APL. (47-48)  Alternatively, therapies 
interrupting cell-adhesion include anti-CD28 Fab, (49) anti-CD40L antibody, (50) and the FDA-
approved natalizumab marketed as TYSABRI®, an anti-α4 integrin antibody. (51)  By impeding 
cell-adhesion or co stimulation, these therapies can prevent lymphocyte recruitment or 
communication with pAPCs.   
Combining these molecular strategies, prior research demonstrated a “bifunctional-peptide 
inhibitor” could suppress T-cell activation. (27, 38-39)  It was hypothesized that efficacy was 
achieved by inhibiting the immunological synapse formation during antigen presentation to 
naïve T cells.   The soluble antigen arrays (SAgAs) developed here were designed as a 
multivalent version of this BPI molecule, which displays antigen (PLP) and the ICAM-1 inhibitor 
LABL explored here.  The antigen and LABL were, therefore, grafted to either a soluble, flexible 
HA or to a PLGA-NP.  For both the HA and PLGA-NP arrays, the peptides were grafted 
according to the density and valency guidelines provided by “Dintzis Rules” (Table 1). (20, 52-
57)  According to these rules, one would expect a more pronounced suppression of EAE 
symptoms for the small, flexible, SAgA. 
Initial studies showed SAgAs provided significant suppression of disease compared to both 
PBS and HA controls.  Studies demonstrated that there may be a dosing optimum to achieve 
maximum disease suppression.  The grafting of antigen and cell-adhesion inhibitor ligands 
significantly increased the ability of HA; a known CD44 antagonist, to provide EAE disease 
suppression.  Results here coincide well with what is reported in the literature.  Kiessling and 
others have analyzed the role cell-surface receptors play in coordinating cellular responses. (58-
59)  Most importantly, they showed the effect was not additive when using a multivalent polymer 
displaying two separate signaling inhibitors.  Rather, the clustering of multiple receptors could 
enhance sensitivity or induce unique cellular responses.  In addition to Kiessling’s work, 
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development of BPI demonstrated that it was the fusion of the antigen and ICAM-1 ligand that 
provided the therapeutic efficacy. (27, 29, 38)   
When the BPI and SAgA results were compared in this study, they were found to be 
equivalent.  The results suggested that efficacy was achieved by the coincident presence of the 
antigen and the cell-adhesion inhibitor.  This hypothesis was tested by delivering arrays 
displaying antigen or only cell-adhesion inhibitor.  Both the HA and NP arrays displaying antigen 
provided little benefit.  The cell-adhesion inhibitor arrays appeared to cause a slight 
exacerbation of the disease, though the difference was not significant.  The data supports the 
hypothesis that to achieve disease suppression both antigen and cell-adhesion inhibitor ligand 
must be delivered together.   
Lastly, the correlation between performance and nanomaterial type was evaluated by 
preparing arrays on either a flexible polymer scaffold or a more rigid nanoparticle scaffold.  Mice 
that received the NP-Arrays were able to maintain body weight throughout the study; however, 
the NP-Arrays did not reduce clinical scores to the same extent as the SAgAs.  This may be due 
to the post injection fate of each of the materials.  The SAgAs demonstrated a high aqueous 
solubility, suggesting that the arrays may be able to drain away from the injection site and into 
lymphatic or systemic circulation.  Conversely, the NP-Arrays were a rigid colloid and most likely 
persisted at the site of injection.  This was evident by a nodule remaining at the injection site for 
the duration of the study, unlike the SAgAs where the nodule dissipated after a few days.  The 
relative immobility of the NP-Arrays after injection may induce recruitment of immune cells to the 
injection site and alter immune response or create a decoy effect.  Nanomaterial chemistry or 
differences in molecular recognition may also affect efficacy.  Further studies are needed, 
however, differences in the clinical data for SAgAs and NP-Arrays suggested that the physical 
characteristics must play a role in the efficacy of the arrays as well.   
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3.5 Conclusions 
SAgAs presenting a disease-specific antigen (PLP) and a cell-adhesion molecule (ICAM-1) 
inhibitor grafted to hyaluronic acid provided significant suppression of EAE.  Additionally, the 
presence of both the antigen and the cell-adhesion inhibitor was necessary to achieve 
suppression.  The physical state of the array also played an important role in efficacy.  When 
dosed with the relatively large NP-ArrayLABL-PLP (~400 nm) the disease suppression was much 
less effective than the hyaluronic acid based SAgALABL-PLP.  While it was demonstrated that both 
the polymer and nanoparticle materials displaying antigen and ICAM-1 inhibitors can improve 
disease scores, it was also shown that the physical characteristics of the material can alter the 
extent of the response. 
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TABLES 
 
Table 1: Overview of peptide concentration and ratios on HA and NP scaffolds.  
Sample LABL Conc. (nMol) PLP Conc. (nMol) Final Ratio 
SAgALABL-PLP 325 275 1.2:1 
SAgALABL 462 - n/a 
SAgAPLP - 286 n/a 
NP-ArrayLABL-PLP 8.2 7.6 1.1:1 
NP-ArrayLABL 16.0 - n/a 
NP-ArrayPLP - 17.6 n/a 
 
 
Table 2: Particle size for NP formulations before and after peptide conjugation. 
Sample ID Pluronic ratio (F108-CHO:F68-OH) 
Particle Size (nm)* 
After fabrication After peptide conjugation  
NP-ArrayLABL-PLP 25:75 171±7.2 420±11 
NP-ArrayLABL 25:75 171±7.2 363±8.4 
NP-ArrayPLP 25:75 171±7.2 420±11 
NP-Blank 0:100 158±1.9 419±12.1** 
*Polydispersity  values were < 0.1.55 
**Samples handled analogously, but no peptide conjugation occurred 
 
Table 3: Outline of individual in vivo studies conducted. 
Study I: Initial Efficacy Study 
Group Dose (nMol PLP/100 μL) Description 
Hyaluronic Acid  Polymer control  
SAgALABL-PLP 100 LABL and PLP grafted to HA 
PBS 0 Negative Control 
Study II: Dose Ranging Study 
Group Dose (nMol PLP/100 μL) Description 
SAgALABL-PLP 100 Low Dose 
SAgALABL-PLP 200 Medium Dose 
SAgALABL-PLP 400 High Dose 
PBS 0 Negative Control 
BPI 100 Positive Control 
Study III: Polymer vs. Nanoparticle Scaffold 
Group Dose (nMol PLP/100 μL) Description 
SAgALABL-PLP 200 HA graft LABL and PLP 
SAgALABL 200 nMol LABL HA graft LABL 
SAgAPLP 200 HA graft PLP 
NP- ArrayLABL-PLP 100 Nanoparticle graft LABL and PLP 
NP- ArrayLABL 100 Nanoparticle graft LABL 
NP- ArrayPLP 100 Nanoparticle graft PLP 
PBS 0 Negative Control 
BPI 100 Positive Control 
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Table 4: Summary of  testing groups and clinical outcomes. 
Treatment Group 
PLP 
conc. 
(nMol) 
Mw 
(Daltons) 
Clinical Data Significance 
compared to PBS Comments 
Score % Weight loss 
Hyaluronic Acid Alone 
 
4.5 
mg/mL** 28000 
Days 11-14, 
p<0.01 
Days 11-14, 
p<0.01 
HA is a natural 
CD44 antagonist 
and provides 
minimal protection 
SAgALABL
 
100* ~70000 None None 
Grafting targeting 
moiety only 
causes disease 
exacerbation 
SAgAPLP 
100 ~80000 None None Grafting antigen showed no effect 
SAgALABL-PLP 
 
 
100 ~80000 Days 11-17, p<0.01 
Days 12-17, 
p<0.05 200 nMol may be 
optimal dose for 
SAgALABL-PLP 
200 ~80000 Days 11-15, p<0.01 
Days 11-15, 
p<0.01 
400 ~80000 Days 12-14, p<0.01 
Days 12-14, 
p<0.05 
Blank NP                    
 
100* n/a None  None 
Nanoparticle 
based SAgA do 
not provide 
suppression of 
EAE 
NP-ArrayLABL              
100 n/a Day 12, p<0.001 None 
NP-ArrayPLP                  
100 n/a Day 12, p<0.001 
Day 12, 
p<0.001 
NP-ArrayLABL-PLP      
100 n/a Day 12, p<0.001 
Days 12-
16,18-22, 
p<0.01 
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FIGURES: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Refractive index GPC chromatogram demonstrating a decrease in retention time of the 
SAgALABL-PLP product (green line) as compared to 31 kDa (blue line) and 17 kDa (red line) HA standards 
indicating an increase in Mw. 
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Figure 2:  (A) Example HPLC chromatogram of peptides hydrolyzed from the conjugate product showing 
the presence of both the Ao-LABL and Ao-PLP peptides. (B) HPLC chromatogram of dialysate showing 
the absence of both the Ao-LABL and Ao-PLP peptides suggesting nearly all peptide was reacted to HA. 
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Figure 3: Comparison of clinical performance of SAgALABL-PLP to negative control (PBS) and polymer 
control (HA).  The data show that SAgALABL-PLP performed significantly better than controls in (A) clinical 
disease score, (B) % change in body weight, and (C) incidence of disease. Differences that were 
statistically significant are summarized in Table 4. 
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Figure 4: Effect of increasing concentration of PLP (100, 200, and 400 nMol) delivered on SAgALABL-PLP.  
The data show that 200 nMol and 400 nMol PLP dose (SAgALABL-PLP-200) performed best in (A) clinical 
disease score, (B) % change in body weight, and (C) incidence of disease. Differences that were 
statistically significant are summarized in Table 4. 
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Figure 5: Effect of HA or NP scaffold on clinical efficacy.  The data show that the HA array (SAgALABL-PLP-
200) performed better than NP based array (NP-ArrayLABL-PLP) in (A) clinical disease score, (B) % change in 
body weight, and (C) incidence of disease. Differences that were statistically significant are summarized 
in Table 4. 
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Figure 6: Effect of multivalent delivery of only antigen (PLP) or only cell-adhesion inhibitor ligand (LABL) 
on HA or NP scaffolds.  Neither the multivalent antigen nor the multivalent cell-adhesion inhibitor 
therapies provided significant suppression of disease as illustrated by overlapping (A) clinical disease 
score, (B) % change in body weight, and (C) incidence of disease results.  Differences that were 
statistically significant are summarized in Table 4. 
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Figure 7:  Effect of mixture of free LABL and PLP peptide.  Mixture of free peptides provided no 
suppression of disease as illustrated by overlapping (A) clinical disease score, (B) % change in body 
weight with the negative PBS control.   
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Supplementary Figures 
 
 
Supplementary Figure I: 1H NMR spectra for Pluronic® (A) F108-OH and (B) F108-CHO showing conversion of –OH 
end groups to CHO. 
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Chapter 4 
Optimization of SAgAs – Effect of target and size 
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INTRODUCTION 
 
Investigation into the root cause(s) of multiple sclerosis requires an understanding of the 
role that CD4+/CD8+ T cells, B cells, and monocytes play in disease progression.  These 
immune cell populations participate in antigen recognition and processing, immune cell 
proliferation, antibody production, and trafficking into the central nervous system (CNS), 
resulting in disease exacerbation. (1-3)  Acknowledging this, therapeutics have aimed to disrupt 
antigen recognition and cell proliferation pathways, or to prevent transport of leukocytes into the 
CNS to avoid further damage.  The multiple sclerosis (MS) therapy Copaxone® utilizes a 
polymeric antigen which appears to induce the proliferation of regulatory T cells (Tregs). (4-6)  
Alternatively, a monoclonal antibody therapy, TYSABRI®, demonstrates that blocking integrin 
α4β1 prevented extravasation of CD8+ T cells into the CNS and slowed disease progression in 
patients with MS. (7-10)  While these therapies provide relief from the symptoms of MS, the risk 
of multiple serious side effects such as severe immune suppression (11) and life-threatening 
secondary infections (12) still exists.  Because of these shortcomings, alternative treatment 
pathways are being investigated.  As a new strategy, Soluble Antigen Arrays (SAgAs) aim to 
interrupt cell signaling during antigen recognition that leads to immune cell proliferation and 
antibody production. 
Antigen-specific treatments, (13) much like vaccines, look to utilize antigen to induce 
specific immune responses.   Presentation of disease-specific antigen as repeating patterns, 
either in high local concentrations or in frequent low doses can induce an inflammatory immune 
response or tolerance. (14-17)  Many studies have focused on the physical context of antigen 
presentation and the effect on the immune response. (18-19)  Recent research has aimed to 
induce, modify, or disrupt the formation of the immunological synapse often by manipulating the 
physical or chemical properties of the antigen. (20-24)  One example, a “bi-functional peptide 
inhibitor” (PLP-BPI), was synthesized by fusing an MS antigen derived from proteolipid protein, 
PLP, and a peptide (LABL) that binds intracellular adhesion molecule-1 (ICAM-1).  PLP-BPI 
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suppressed Experimental Autoimmune Encephalomyelitis (EAE) significantly compared to 
controls. When the ICAM-1 targeting peptide was replaced by a peptide (IBR) that binds the 
ICAM-1 receptor leukocyte-associated function antigen-1 (LFA-1), preliminary data suggested 
an increase in efficacy, however, this is still being investigated. (25-26)   
SAgAs aim to tailor both the physical and chemical context of antigen presentation.  
Initial SAgA design utilized LABL to target ICAM-1 and a therapeutic size of ~80 kDa in order to 
encourage multivalent interaction with immune cells while avoiding rapid clearance after 
subcutaneous (SC) injection.  (27)  Therefore, SAgAs targeting either ICAM-1 or LFA-1 were 
explored here.  Controlling SAgA location was also expected to be important in treating MS 
since antigen recognition has been shown to occur in the draining lymphatics for the CNS. (28)  
The lymphatics present a unique, highly organized microenvironment rich in subpopulations of 
APCs, T cells, and B cells participating in disease progression. (29)  SAgA size was expected to 
affect the drainage into, residence time within, and clearance from lymph nodes, thereby 
potentially altering the clinical immune response.   Thus, the chemical (targeting) and physical 
(size) characteristics of SAgAs were explored as a means to suppress EAE.   
In EAE, disease progression is characterized by suspected protein antigens, such as 
proteolipid protein (PLP), myelin basic protein (MBP), and myelin oligodendrocyte glycoprotein 
(MOG), (30) acting as immunogenic epitopes and activating naïve CD4+ T-cells.  After antigen 
presentation by pAPCs, these activated CD4+ T cells can differentiate into Th1 or Th17 effector 
cells.  More importantly, these events lead to the production of specific cytokines such as IL-2, 
IFN-γ, and TNF-α.  In addition, Th17 cells secrete cytokines such as IL-17, and are further 
activated by cytokines IL-6, IL-23, and TGF-β. (1, 31)  Disease suppression is expected to be 
related to the proliferation of adaptive regulatory T cells (Tregs) which may be linked to the 
expression of immunosuppressive cytokines, IL-10 and/or TGF-β. (32-33)  Here, IL-2, IL-4, IL-
10, IL-17, IFN-γ, and TNF-α concentrations in blood were monitored to help define the immune 
response to SAgAs differing in size or target (ICAM-1 or LFA-1). (34)   
70 
 
 
MATERIALS AND METHODS 
Materials.  Hyaluronic acid (HA), with an average molecular weight of 17 and 31 kDa were 
purchased from Lifecore.  Analytical grade acetonitrile, synthesis grade trifluoro acetic acid 
(TFA), and PBS buffer were purchased from Fisher Scientific.  Research grade sodium acetate, 
acetic acid, and D2O and heparin were purchased from Sigma.  Water was provided by a 
Labconco Water PRO PS ultrapure water purification unit.   
Mice. Four – 6 weeks old SJL/J (H-2s) female mice were purchased from The Jackson 
Laboratory.  Animals were housed under specified pathogen-free conditions at The University of 
Kansas Animal Care Facility. The University of Kansas Institutional Animal Care and Use 
Committee approved all protocols involving live mice. 
Peptide Synthesis.  9-fluorenylmethyloxycarbonyl-protected amino acid chemistry on 
polyethylene glycol-polystyrene resins was used to synthesize the aminooxy peptides.  Peptides 
synthesized for this study were aminooxy-LABL (aminooxy-ITDGEATDSG, Ao-LABL), a ligand 
of ICAM-1, aminooxy-IBR (aminooxy–GGGPRGGVS, Ao-IBR), a ligand of LFA-1, and 
aminooxy-PLP (aminooxy–HSLGKWLGHPDKF, Ao-PLP), an antigen derived from proteolipid 
protein amino acids 139-151 (PLP137-151).  Each peptide was deprotected, cleaved from resin, 
and isolated by precipitation in ether. Preparatory High Performance Liquid Chromatography 
(HPLC) was employed to purify the peptides, followed by lyophilization.  Purity/content and 
peptide identity were verified using analytical HPLC and Mass Spectroscopy.  PLP-BPI, a fusion 
of PLP and LABL (HSLGKWLGHPDKF-AcGAcGAc-ITDGEATDSG), was synthesized and 
purified as previously reported.(35) 
Reaction of Aminooxy Peptides to Polymers.  The HA scaffolds were dissolved into 20 mM 
Acetate buffer (pH 5.5 + 0.1 pH units) and aminooxy reactive peptide(s) added.  When multiple 
peptide species were used, each was weighed separately, and then both peptides were added 
simultaneously.  Reaction solution pH was adjusted back to pH 5.5 + 0.1 pH units after addition 
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of the peptide(s).  Reaction solutions were stirred at for ~ 16 hr.  After the reaction, the soluble 
antigen array (SAgA) product was purified by extensive dialysis to remove any unreacted 
peptide, and then lyophilized. 
High Performance Liquid Chromatography. Reversed phase HPLC (SHIMADZU) using a 
Vydac HPLC protein and peptide C18 column was used to quantified conjugated peptide. The 
HPLC system was made up of an SCL-20A SHIMADZU system controller, LC-10AT VP 
SHIMADZU liquid chromatograph, SIL-10A XL SHIMADZU auto-injector set at 75 μL injection 
volume, DGU-14A SHIMADZU degasser, sample cooler, and SPD-10A SHIMADZU UV-vis 
detector (220 nm).  The HPLC-UV system was controlled by a personal computer equipped with 
SHIMADZU class VP software. A gradient elution was conducted at constant flow of 1 mL/min, 
from 100% A to 35% A (corresponding to 0% B to 65% B) over 50 min, followed by an isocratic 
elution at 75% B for 3 min. The mobile phases were (A) acetonitrile-water (5:95) with 0.1% TFA 
and (B) acetonitrile-water (90:10, v/v) with 0.1% TFA. After each analysis, the cartridge was 
equilibrated at initial conditions at 1 mL/min flow rate for 5 min with A.  
Preparation of Near Infrared Dye IR-820.  To prepare the dye, 125 mg 6-aminocaproic acid 
was dissolved in dry DMF (20mL).  TEA (130 μL) was added and the mixture was allowed to stir 
under argon for ~5 min.  Then, 500 mg IR-820 was added.  A reflux condenser was attached 
and the mixture was heated to 85°C for 3 hr in the dark. After the reaction the solvent was 
removed using a rotovap (Bruker) and placed under vacuum over night to dry.   
Conjugation of IR-820 to Hyaluronic Acid.  IR-820-5aminohexanoic acid dye was dissolved 
into water.  EDC was added and the solution pH was adjusted to 4.5.  Then, DMAP was added 
and the solution was stirred, in the dark, for 5 min.  After activation of IR-820 (5 min), hyaluronic 
acid was added to the flask and the solution was stirred in the dark, for 48 hours.  The product 
was purified by dialyzing against 95% EtOH for 8 hours, then against water twice (8 Hours a 
time) in the dark.  The retentate was lyophilized and the dye content of the product was 
confirmed using NMR (Supplementary Table 1). 
72 
 
Nuclear Magnetic Resonance Spectroscopy.  For dye content analysis, samples were 
dissolved in D2O to a concentration of 10 mg/mL.  H1 spectra were acquired on a Bruker 
400MHz spectrometer at 25 °C. 
Induction of EAE and Therapeutic Study. Four – 6 week-old SJL/J female mice were 
immunized subcutaneously (s.c) with 200 μg of PLP139–151 in a 0.2 mL emulsion composed of 
equal volumes of complete Freund’s adjuvant (CFA) containing killed Mycobacterium 
tuberculosis strain H37RA (final concentration of 4 mg/mL; Difco) and phosphate-buffered saline 
(PBS) containing PLP. The PLP139–151/CFA emulsion was administered to regions above the 
shoulders and the flanks (total of four sites; 50 μL at each injection site).  Additionally, 200 
ng/100 μL of pertussis toxin (List Biological Laboratories Inc.) was injected intraperitoneally (i.p.) 
on the day of immunization (day 0) and 2 days post-immunization.  Mice received s.c. injections 
of each sample, equivalent to 200 nMol PLP /100 μL, on days 4, 7, 10.  One hundred μL of each 
vehicle was injected for all samples and controls.  Disease progression was evaluated blindly by 
the same observer using clinical scoring as follows: 0, no clinical signs of the disease; 1, tail 
weakness or limp tail; 2, paraparesis (weakness or incomplete paralysis of one or two hind 
limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, paraplegia with forelimb 
weakness or paralysis; and 5, moribund (mice were euthanized if they were found to be 
moribund). Body weight was also measured daily. 
Cytokine Analysis.  Blood samples were taken from each mouse via mandibular bleeds (~100 
uL) on days 0, 6, 12, 18, 25.  To ensure there was enough sample to perform ELISA cytokine 
testing blood from, two mice within the same group was pooled at each time point for a total of 
four samples per group.  Samples were collected in heparin-containing tubes and centrifuged to 
separate red blood cells.  Plasma was collected and sent for cytokine analysis to the Cytokine 
Core Laboratory at the University of Maryland.  The cytokines analyzed were IL-2, IL-4, IL-10, 
IL-17, TNF-α, and TGF-β. 
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In vivo Imaging.  In vivo imaging was completed using the Maestro Imaging Suite.  Animals 
were anesthetized using an isoflurane vaporizer and IR-820 labeled SAgA was injected s.c. at 
the base of the neck.  After injection images were taken of the animal’s top, left, bottom, and 
right side by rotating the animal in the exposure pane.  The animal was imaged at defined time 
points over a 24 hour period to track the drainage and clearance of the SAgA from the injection 
site. 
Statistical Analysis.  Statistical differences were determined by comparing treated groups to 
the negative control (PBS) for clinical disease score and body weight.  A one-way analysis of 
variance (ANOVA) followed by Fisher’s least significant difference was applied to these data.  
For individual clinical scores and cytokine values T test was employed.  All analyses were 
performed using GraphPad Software (GraphPad Software Inc.). 
 
RESULTS 
Characterization of Polymeric Soluble Antigen Arrays.  The concentration of peptide grafted 
to the HA backbone was quantified by HPLC. Peptide was released from HA by incubating the 
SAgA product in pH 2 mobile phase buffer at room temperature.  Chromatographs 
demonstrated the presence of the Ao-LABL or Ao-IBR peptide, and the Ao-PLP peptide at 
approximately the desired 1:1 ratio for all products.  All peptides were conjugated at a high level 
of efficiency, >90% (Table 1).  
The therapeutic efficacy of various SAgAs was evaluated in the EAE model induced in 
SJL/J mice.  The study design is outlined in Table 2.  Typically, disease onset occurs at 
approximately day 8 and progresses to remission around day 20.  Disease is manifested by 
physical signs, such as weakness, paralysis of the tail and limbs, and loss of body weight. 
Injections of each sample were given subcutaneously at the base of the neck, on days 4, 7, 10. 
Effect of Cell-adhesion Target on Suppression.  SAgAs targeting either ICAM-1 (SAgALABL-
PLP) or LFA-1 (SAgAIBR-PLP) performed significantly better than the negative PBS control in 
74 
 
clinical score (p < 0.01, for days 14 & 17-19 for both) (Figure 1-A).  Additionally, the mice 
treated with the targeted SAgAs also had significantly better maintenance of body weight (p < 
0.05, for days 15-21 for SAgALABL-PLP and day 18 for SAgAIBR-PLP) compared to the negative 
control PBS group (Figure 1-B).   Of all the treated groups, only the SAgAIBR-PLP had mice that 
never developed EAE as identified by a clinical score of >1 (Figure 1-C).  This data compared 
well to the positive PLP-BPI control and no statistical difference was seen between treatments 
with SAgAs compared to the positive control. 
Effect of SAgA Size on Suppression.  Both the 50 kDa and 80 kDa SAgALABL-PLP and the 50 
kDa and 80 kDa SAgAIBR-PLP inhibited the progression of EAE as evidenced by very low clinical 
scores compared to the negative PBS control (Figure 2-A).  Clinical suppression was 
significantly improved over PBS treatment for the 50 kDa and 80 kDa SAgALABL-PLP (p < 0.05, for 
days 14 & 17 and 14 & 17-19, respectively) as well as the 50 kDa and 80 kDa SAgAIBR-PLP (p < 
0.05, for days 14 & 17-19 for both).  The treated mice also had better maintenance of body 
weight (Figure 2-B) compared to the negative control PBS group for all tested groups.  
Complete statistics are outlined in Table 2.   Additionally, the smaller 50 kDa SAgAIBR-PLP 
delayed the onset of disease better than the 80 kDa SAgAIBR-PLP (p<0.05, day 11) with initiation 
of disease occurring two days later with the 50 kDa SAgAIBR-PLP.  A high percentage of animals 
treated with the 50 kDa SAgAIBR-PLP never developed clinical scores > 1 (Figure 2-C).  This data 
compared well to the positive PLP-BPI control and no statistical difference was seen between 
treatments with SAgAs as compared to the positive control. 
In vivo imaging of SAgAs.  Both the 50 and 80 kDa SAgALABL-PLP were imaged and compared 
to a 30 kDa HA (the 80 kDa backbone) and a 70 kDa HA that was similar in Mw to the final 
products.  After injection of the IR820-labeled HA or SAgALABL-PLP, the drainage from the 
injection site was tracked and images were acquired over 24 hours (Figure 3).  The 30 kDa HA 
(Figure 4-A) appeared to drain from the injection site and into the local lymph nodes quickly, and 
was cleared by 1440 min.  The 70 kDa HA (Figure-4B) showed a relatively shorter drainage 
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time with the labeled HA detectable only until 500 min.  For the labeled SAgA conjugates, the 
drainage time more closely resembled the slow drainage of the smaller 30 kDa HA rather than 
the 70 kDa HA.  The 50 kDa SAgALABL-PLP showed drainage away from the injection site and 
suggested drainage into the local lymphatics.  Clearance was not achieved until 1440 min, 
similar to the 30 kDa HA.  The larger 80 kDa SAgALABL-PLP showed similar drainage into the 
lymphatics, but it was still visible even after 1260 minutes.  While these results are qualitative, 
they do provide some insight into the location of the SAgA conjugates at different time points. 
Effect of SAgA on Cytokine Profile.  The plasma samples were analyzed for 6 cytokines; IL-2, 
IL-4, IL-10, IL-17, TNF-α, and IFN-γ. Baseline levels of each cytokine were measured at Day 0 
before disease induction.  Within each testing group, blood was pooled from two mice resulting 
in an n=4.  When statistics were performed deviations from n=4 due to samples being below the 
level of detection for cytokine measurements are noted.  IL-2 and IL-10 were below the limit of 
detection in all samples.   
Examination of IL-4, IL-17, TNF-α, and IFN-γ suggested that treatment with SAgAs led to 
differences in the cytokine production profiles when compared to both the PBS and PLP-BPI 
controls.  The largest differences were seen with the levels of IFN-γ, TNF-α, and IL-17 data, 
while smaller differences were seen with IL-4 levels (Figure 4).  Mice receiving PBS had very 
high average concentrations of IFN-γ by day 6 (72 pg/mL); however, groups treated with SAgAs 
of PLP-BPI suppressed IFN-γ production.  The PLP-BPI (31 pg/mL) and the 50 kDa SAgAIBR-PLP 
(38 pg/mL) treatments provided moderate suppression with an average of ~40% reduction in 
peak expression of IFN-γ on Day 6.  The lowest IFN-γ levels were seen with both the 50 and 80 
kDa SAgALABL-PLP (12 and 14 pg/mL respectively) and the 80 kD SAgAIBR-PLP (6 pg/mL), 
correlating to an ~80-90% reduction compared to the PBS controls. When a T-test was 
performed for Day 6 measurements, the 50 and 80 kDa SAgALABL-PLP and 80 kDa SAgAIBR-PLP 
were significantly different than the PBS. For the 80 kDa SAgALABL-PLP and PBS groups n=3. 
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For both TNF-α and IL-17, treatment with SAgA or PLP-BPI led to an increase in the 
circulating cytokine concentrations compared to the PBS control.  Similar to the IFN-γ data, 
peak concentrations of TNF-α occurred on day 6 for the PBS samples; however, these levels 
were very low at 1.8 pg/mL.  The PLP-BPI reached 3.1 pg/mL of TNF-α on day 6.  The 50 kDa 
SAgALABL-PLP (3.7 pg/mL), 80 kDa SAgALABL-PLP (3.4 pg/mL), and 80 kDa SAgAIBR-PLP (2.6 pg/mL) 
also reached peak levels on day 6.  The 50 kDa SAgAIBR-PLP showed peak concentrations at 
days 6 and 18 (3.7 & 4.2 pg/mL).   
The IL-17 data for the PBS control showed a peak concentration at day 6 (23 pg/mL).  
The 80 kDa SAgAIBR-PLP (45 pg/mL) and the PLP-BPI (40 pg/mL) control gave slightly elevated 
levels of IL-17; however, the PLP-BPI maintained elevated levels through day 12 (31 pg/mL), 
then returned toward baseline.  Interestingly, peak concentrations at both days 6 and 18 were 
seen for the 50 kDa SAgAIBR-PLP (45 & 82 pg/mL), and both the 50 kDa SAgALABL-PLP (66 & 21 
pg/mL) and 80 kDa SAgALABL-PLP (45 & 41 pg/mL).   
Finally, IL-4 concentrations, though low, showed similar results for all samples (0.25-
0.35 pg/mL), except for the 50 kDa SAgALABL-PLP and 80 kDa SAgAIBR-PLP, which had increased 
levels.  The IL-4 levels for 50 kDa SAgALABL-PLP were similar to all other samples on day 6 (0.25 
pg/mL), but, increased on day 12 (1.1 pg/mL).  The 80 kDa SAgAIBR-PLP  level decreased on day 
6 to a concentration of 0.73 pg/mL.   After day 6, the 80 kDa SAgAIBR-PLP IL-4 level continued to 
decrease, however, became elevated at the study end (0.2 pg/mL).  
 
DISCUSSION 
Antigen recognition and the response propagated by immune cells are key events in 
progression of autoimmune diseases such as multiple sclerosis.  Many of the current 
therapeutic approaches attempt to interfere with these events either directly or through the 
manipulation of secondary pathways such as cytokine production.  Traditionally, these 
therapeutic pathways have been targeted independently; for example, monoclonal Abs targeting 
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specific receptors (e.g. cell-adhesion or co-stimulation) or altered peptide ligands interfering with 
antigen presentation.  Unfortunately, these treatments often lack long term efficacy or result in 
deleterious side effects, requiring a new therapeutic strategy.   
SAgAs were rationally designed to display multiple copies of antigen alongside inhibitors 
of immune cell adhesion.  A “bi-functional peptide inhibitor” developed by Siahaan and others, 
used a fusion peptide of the EAE disease-specific antigen (PLP) and a cell-adhesion inhibitor 
(LABL) connected via a linker.  The goal of this construct was interference with the formation of 
the immunological synapse.  Reports showed that PLP-BPI molecules achieved clinical efficacy 
in EAE by preventing APC activation of naïve T cells.(1, 25, 35-36)  Here, this validated 
molecular strategy was paired with multivalent antigen display.  Seminal papers from Dintzis 
and others systematically demonstrated that immunosuppression could be achieved by 
controlling the number and density of grafted antigens along the polymer. (37-39)  The “soluble 
antigen arrays” investigated in this research aimed to combine the success of both the PLP-BPI 
and multivalent antigen arrays by presenting multiple copies of both antigen and cell-adhesion 
inhibitors.   
Previously, SAgAs that presented both the EAE antigen, PLP, and the ICAM-1-targeting 
peptide, LABL, delayed the onset of disease and lowered EAE clinical scores, similar to that of 
PLP-BPI (Chapter 3).  Unpublished results from additional studies suggested that PLP-BPIs that 
targeted LFA-1 (40-41) rather than ICAM-1 were able to suppress EAE with greater efficacy.  
Therefore, the effect of substituting IBR for LABL on SAgAs was hypothesized to further 
improve efficacy.  When IBR was substituted for LABL on the SAgAs, however, no significant 
change in efficacy was seen.  This result, while not in agreement with what had been observed 
with PLP-BPI, was not unexpected.  In previous work, dendritic cells (DCs) treated with 
nanoparticles displaying LABL or IBR showed a similar reduction in T cell binding, perhaps 
suggesting minimal differences between these two cell-adhesion inhibitors when presented as 
multivalent arrays. (42)  Here, clinical efficacy was similar whether the SAgAs displayed the cell-
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adhesion inhibitor LABL or IBR.  This observation led to the investigation of alternative SAgA 
characteristics that could improve therapeutic performance. 
Next, SAgA Mw was reduced in an effort to promote drainage to regional lymph nodes 
and animal response was monitored for SAgAs targeting either ICAM-1 or LFA-1.  The 
efficacies of all the different SAgAs were similar to one another as well as to the PLP-BPI 
positive control.  While the clinical scores were similar, the smaller SAgAs delayed the onset of 
disease and decreased the incidence of disease.  Smaller arrays with ~20 total grafted peptides 
provided increased efficacy over larger arrays with ~32 grafted peptides.  While the molecular 
architecture is no doubt important, the improvement from a small change in Mw motivated 
further investigation into the post-injection fate of the SAgA materials (Figure 3).  Real-time, in 
vivo imaging results showed that differences in SAgA Mw indeed affected the relative rate of 
drainage from the injection site to the regional lymphatics.  Smaller 50 kDa SAgAs could no 
longer be detected while 80 kDa SAgAs remained visible after 24 hours in what appeared to be 
the local lymphatics near the injection site.  Thus, more rapid drainage away from the injection 
site and toward the lymphatics may explain the difference clinical results.  
To define the immunological mechanisms behind the observed responses, plasma 
samples were taken from each mouse and six different cytokines were monitored throughout 
the course of the in vivo studies.  Cytokines provide insight into cellular responses and possible 
mechanistic pathways.  IL-2 and IL-10 were below the limit of detection; however, this was not 
unexpected as circulating levels of these cytokines are recognized to be very low.  Compared to 
PBS, all treatments affected the IL-4, IL-17, TNF-α, and IFN-γ levels during the course of the 
study.  Control mice treated with PBS produced high levels of IFN-γ, while the levels in mice 
treated with SAgAs or PLP-BPI were suppressed.  High levels of IFN-γ are associated with a 
Th1 phenotype, which dampens the Th2 response. (43)  In the presence of the SAgAs, the 
phenotype seemed to be skewed away from an INF-γ promoted Th1 phenotype and towards a 
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Th2 response. Of equal importance, levels of TNF-α were increased in the treated groups. 
Since TNF-α can induce apoptosis in the CD4+ T cell population, future studies will aim to 
determine apoptosis in T cells of the treated animals. (44) Levels of IL-4 did not vary 
significantly between the treated groups and the PBS controls. With the exception of the group 
treated with 50 kDa SAgALABL-PLP, IL-4 may therefore not contribute significantly to the observed 
differences between the groups.   
Cytokines IL-17, TNF-α, and IFN-γ are typically seen as pro inflammatory in autoimmune 
diseases while IL-4 is expected to dampen the Th2 response, stimulating immune suppression 
or tolerance.  Recent studies, however, have suggested that cytokines such as IL-17 and TNF-α 
can induce both inflammatory and/or anti-inflammatory or tolerogenic responses depending on 
the other cytokines expressed. (32, 45)  These recent studies go against conventional thinking 
that IL-17, a direct measurement of Th17 population, is a measurement of disease progression.  
Although the negative PBS control had high levels of serum IFN-γ concentration, the same 
group produced low levels of both TNF-α and IL-17, cytokines traditionally viewed as pro 
inflammatory.  In contrast, the observed reduction in IFN-γ in the treated groups was associated 
with a corresponding increase in IL-17 and alteration in TNF-α.  Historically, Th17 and Th1/Th2 
responses have been observed as independent pathways, however, recent research suggests 
Th17 cell populations can exhibit plasticity and produce IL-17 or IFN-γ.  In the case of Th17-
mediated autoimmune diseases such as MS this plasticity could lead to a tolerogenic response, 
(32) a hypothesis that would fit the observed data well.  It is worth noting that IL-10 signaling in 
regulatory T cells mediates suppression of the Th17 phenotype during inflammation. (46-47)  
This is accomplished by up regulation of the IL-10 receptor on the Th17 cells during an immune 
response.  As mentioned, IL-10 was undetectable in any group of mice, therefore, it is currently 
unclear if IL-10 levels can be regulated by SAgAs.  
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The bimodal cytokine distributions for certain SAgA therapeutics were perhaps the most 
intriguing data arising from this study.  Multiple SAgA species elicited a bimodal production 
cycle of TNF-α and IL-17 cytokines.  Concentration maximums for these cytokines at days 6 and 
18 could suggest initiation of the adaptive or long-term immune response.  The samples that 
showed the largest peaks, 50 kDa SAgAIBR-PLP, 50 kDa SAgALABL-PLP, and 80 kDa SAgALABL-PLP, 
also exhibited very effective disease suppression.  While all groups performed similarly with 
regards to clinical score and body weight maintenance, this variation in the cytokine response 
may play a vital role in an immune response leading to long-term efficacy. 
 
CONCLUSIONS 
SAgAs targeting ICAM-1 or LFA-1 were evaluated and either target provided similar 
suppression of EAE.  Decreasing the Mw of SAgAs from 80 kDa to 50 kDa delayed the disease 
onset.  In vivo imaging revealed differences in drainage profiles between the 50 kDa and 80 kDa 
SAgAs with the larger complex having extended residence near the injection site.  Treatment 
with 50 and 80 kDa SAgALABL-PLP and 80 kDa SAgAIBR-PLP demonstrated decreased production of 
the pro inflammatory cytokine IFN-γ compared to the PBS control.  Additionally, the 50 kDa 
SAgAs demonstrated differences in the production of IL-17, while the 50 kDa SAgALABL-PLP and 
80 kDa SAgAIBR-PLP altered the TNF-α profile compared to PBS.  The physical characteristics of 
SAgAs had a significant impact on the chemical outcomes and immune responses observed in 
the EAE mouse model. 
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TABLES 
Table 1: Overview of peptide concentrations as determined by HPLC and resulting peptide ratio grafted to HA.  
Sample LABL or IBR Conc. (nMol) PLP Conc. (nMol) Final Ratio 
50 kDa SAgALABL-PLP 
 
475 300 1.5:1 
80 kDa SAgALABL-PLP 
 
396 283 1.4:1 
50 kDa SAgAIBR-PLP 
 
297 377 1:1.3 
80 kDa SAgAIBR-PLP 
 
262 334 1:1.3 
 
Table 2: Outline of design and statistics of in vivo studies 
Group PLP conc. (nMol) 
Mw 
(Da) 
Clinical Significance vs. PBS 
Score % Weight loss 
50 kDa SAgALABL-PLP 
 
200 
~50000 p< 0.05, Days 14 & 17 n/a 
80 kDa SAgALABL-PLP
 
~80000 p< 0.05, Days 14, 17-19 p< 0.05, Days 15-21 
50 kDa SAgAIBR-PLP 
 
~50000 p< 0.05, Days 14, 17-19 p< 0.05, Day 19 
80 kDa SAgAIBR-PLP 
 
~80000 p< 0.05, Days 14, 17-19 p< 0.05, Day 18 
PLP-BPI  ~3000 
p< 0.05, Days 14 & 
17 p< 0.05, Day 16 
PBS 0 n/a n/a n/a 
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FIGURES 
 
Figure 1: Comparison of clinical performance of SAgALABL-PLP targeting ICAM-1 and SAgAIBR-PLP targeting LFA-1 to 
negative control (PBS).  The data show that SAgAs performed similarly to each other and significantly better than 
PBS control in (A) clinical disease score, (B) % change in body weight, and (C) incidence of disease. Differences that 
were statistically significant are summarized in Table 2. 
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Figure 2: Comparison of clinical performance of two different Mw SAgAs to negative control (PBS).  The data show 
that smaller 50 kDa SAgAs performed significantly better than larger 80 kDa in delaying disease onset.  Both SAgAs 
performed significantly better than PBS control in (A) clinical disease score, (B) % change in body weight, and (C) 
incidence of disease. Differences that were statistically significant are summarized in Table 2. 
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Figure 3: In vivo images of mice injected with IR820-HA or IR820-SAgAs.  The injection site is indicated by the arrow 
and the relative location of cervical  lymph node packets by the outlined circle. Animals were injected with (A) 35 kDa 
HA, (B) 70 kDa HA, (C) 50 kDa SAgALABL-PLP, or (D) 80 kDa SAgALABL-PLP. 
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Figure 4:  Comparison of cytokine concentration for SAgAs versus controls as determined by ELISA.  
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Supplementary Tables A  
 
Table 1: IR-820 concentration conjugated to HA polymers of 31 and 17 kDa as determined by NMR 
Mw 31000 17000 
Mw of monomer of HA 379 379 
subunits of HA 81.8 44.9 
Ref of Integration 245.4 134.6 
triplet at 1.18ppm 2.9 2.4 
#dyes/subunit 1.4 1.2 
#dyes 117.8 53.6 
wt% 4.0 5.9 
B 
*Also used for synthesis of 50 and 80 kDa SAgAs 
 
C 
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Chapter 5 
Conclusions and Future Directions 
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 Nanomaterials are unique in that they can be designed to simultaneously engage both 
physical and chemical immune response pathways.  In addition the size, shape, charge, etc. 
can be modified to compartmentalize nanomaterials to target tissues.  This design flexibility has 
led to the development of unique strategies to modulate immune response.  While mechanisms 
of action may differ, applications using nanomaterials to tailor immune response primarily focus 
on the antigen presentation profile along the nanomaterial surface.  Controlling the number, 
density, and presentation pattern of antigens are all points of interest. 
 The goal of this work has been to develop a multivalent nanomaterial that presents both 
antigen and cell-adhesion inhibitor simultaneously in order to suppress experimental 
autoimmune encephalomyelitis.  HA polymer and PLGA nanoparticles were used as scaffolds to 
synthesize “antigen arrays,” on which antigen, PLP, and cell-adhesion inhibitor, LABL or IBR, 
were conjugated using novel N-oxime chemistry.  These materials were characterized to 
determine reaction efficiency, ratio of conjugated peptides, and effect of material size/solubility 
(polymer vs. nanoparticle) on in vivo efficacy.  Analysis by HPLC demonstrated that N-oxime 
chemistry provided high reaction efficiency for grafting peptides to HA.  Additionally, this novel 
synthetic approach also allowed for simultaneous conjugation of two peptide species in 
equimolar ratios via a single step reaction.  Further analysis showed that these antigen arrays 
demonstrated conjugate stability at physiological pH.  Initial in vivo studies showed that the 
Soluble Antigen Arrays (SAgAs) built on the HA backbone were able to suppress disease 
progression more significantly than HA or PBS treatments as evidenced by the reduction in 
clinical score and improved maintenance of body weight.  The dose level of SAgAs was 
optimized and tested against PLGA nanoparticle arrays.  While both treatments demonstrated 
similar results for weight maintenance, only the SAgAs demonstrated significant clinical efficacy. 
 The effect of co-grafting ICAM-1 or LFA-1 alongside antigen as well as the role of size of 
the manufactured SAgAs, was also investigated.  Clinical scores and weight were monitored 
and cytokine profiles were collected for animals treated with the various SAgA.  The SAgAs 
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targeting ICAM-1 or LFA-1 both produced similar clinical scores; however, the SAgAs targeting 
LFA-1 changed the IFN-γ,  TNF-α, and IL-17 cytokine profiles compared to SAgAs targeting 
ICAM-1.  This result demonstrated the complex nature of the immune response since similar 
clinical efficacy was achieved in spite of different cytokine responses.  When SAgA size was 
decreased from 80 kDa to 50 kDa significant differences were seen in the ability of the smaller 
arrays to delay the time to disease onset.  These results were corroborated for both SAgA 
targeting species.  Additionally, the cytokine profiles were altered by this decrease in SAgA Mw 
with the smaller SAgAs producing higher levels of IFN-γ and IL-17 compared to the larger 
arrays. 
Future work with these SAgAs should further examine the chemical stability of the 
manufactured materials, optimize the targeting and drainage characteristics (e.g. size, shape, 
solubility), and investigate the drainage kinetics.  Material characterization should focus on both, 
optimizing the synthesis conditions as well as evaluating the storage and blood plasma stability 
of the manufactured materials.  To date, the synthesis of the materials has been derived from 
conditions reported in the literature for similar reactions.  Reaction efficiency may be increased 
and reaction time decreased through manipulation of buffer composition, concentration, pH, 
temperature, or catalyst.  Additionally, the purification strategies of the manufactured materials 
may be optimized to increase product yield.  Beyond material manufacture, SAgAs could be 
evaluated for their blood plasma and long-term storage stability.  The studies completed here 
demonstrated that both cell-adhesion inhibitor and disease-specific antigen should be co-
delivered along either a soluble polymer or nanoparticle to achieve clinical success.  An 
understanding of the stability of the materials is crucial in predicting material efficacy. 
 In addition to understanding the physical stability of the manufactured SAgAs, optimizing 
the cell receptor target and/or therapeutic size provides options for therapeutic enhancement.  
Also, the completed studies targeted a 1:1 ratio of cell-adhesion inhibitor: MS antigen while still 
maintaining the total hapten density as established by “Dintzis rules.”  The effect of antigen or 
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cell-adhesion inhibitor number/density should be tested as illustrated in Table 1.  Studies 
completed here demonstrated that polymers displaying only cell-adhesion inhibitor or only 
antigen did not suppress EAE while a 1:1 ratio provided significant suppression.  This suggests 
that coincident display of both antigen and cell-adhesion inhibitor is necessary; however, the 
tested 1:1 ratio is not guaranteed to be the optimum.  Systematically varying the LABL or IBR 
and PLP ratio as illustrated in Table 1 may enhance clinical results. 
 Pilot studies in this thesis investigated the role of co-delivery of cell-adhesion and 
antigen peptides via the same polymer (SAgALABL-PLP) as opposed to a mixture of homopolymers 
(e.g. only LABL or only PLP).  Delivery of the homopolymers individually demonstrated no 
efficacy; however, when delivered as a mixture, disease suppression was achieved similar to 
the SAgALABL-PLP and PLP-BPI controls (Figure 1-A).  Animals treated with the homopolymer 
mixture also maintained body weight similar to the controls (Figure 1-B).  The presence of the 
two signals appeared responsible for clinical efficacy without requiring conjugation to the same 
polymer.  To further evaluate this, homopolymers should be injected as a mixture, as well as 
separately into the same injection site and at different sites.    
Lastly, the remaining SAgA characteristic that may provide added efficacy would be the 
physical size of the final SAgA product.  Initial in vivo imaging studies suggested that 
manipulating SAgA size altered the drainage characteristics.  Additionally, this slight difference 
in drainage profile produced significant differences in the clinical scores as well.  Clinical 
efficacy may be correlated to the ability of the material to drain away from the injection site and 
into the surrounding tissues.  It is suspected that relatively rapid transit to the lymph nodes 
draining the CNS may be an important effect or of response.  By manipulating final Mw, the 
mobility of the synthesized SAgAs is expected to change as outlined in Table 2. After synthesis, 
each SAgA should be evaluated in the EAE model, using imaging to correlate drainage to 
clinical efficacy. 
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The effect of multivalent antigen presentation was preliminarily explored to determine the 
cross-reactivity of the SAgA therapies.  Extended residence time, as suggested by in vivo 
imaging studies, and unique multivalent antigen presentation compelled an initial evaluation of 
SAgAs displaying non-PLP antigens for treated PLP-induced EAE.  The peptide epitope of 
myelin oligodendrocyte glycoprotein (MOG, Ao-GWYRSPFSRVVHL) was conjugated to HA with 
a previously evaluated cell-adhesion inhibitor (LABL or IBR).  In addition, an array displaying 
antigen only (MOG and PLP) was tested.  The MOG SAgAs were then injected into animals with 
EAE induced using PLP following the procedure outlined in previous chapters.  Interestingly, the 
SAgALABL-MOG and SAgAMOG-PLP showed decreased clinical scores; however, disease 
suppression was not significant when compared to PBS (Figure 2-A).  These results concurred 
with the weight maintenance data (Figure 2-B); however, disease onset did not seem to be 
affected with all mice developing EAE at similar times (Figure 2-C). 
SAgA clinical efficacy can be optimized by systematically investigating SAgA physical 
characteristics such as size, drainage profiles, and antigen presentation motifs.  In addition to 
these physical parameters, evaluation of the optimized SAgAs effect on binding and cytokine 
production in both in vitro and animal models experiments will help to explain the cellular 
responses to the SAgAs.  Collectively, these recommended studies will help to define the 
mechanisms of action of SAgAs and will offer insights into new design strategies for further 
improving performance.   
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TABLES 
Table 1: Proposed study to examine the effect of cell-adhesion to antigen ratio. 
SAgA LABL cell-adhesion inhibitor Mol % PLP antigen Mol % Outcome 
PLP and LABL (variable 
ratios) grafted to HA 
0 100 Limited Suppression 
25 75 
Varied Suppression 50 50 
75 25 
100 0 Disease Exacerbation 
 
Table 2: Proposed SAgA to investigate effect of therapeutic Mw. 
SAgA Mw Hyaluronic acid scaffold (kDa) Theoretical Array Mw (kDa) Anticipated Drainage Profile 
PLP and LABL (1:1) grafted 
to HA 
1 2.9 Rapid drainage, Leakage to circulation 
6.4 16.6 
Primarily localized lymphatic 
uptake 17 49.7 
31 80.5 
75 219.2 Minimal drainage, depot 
effect 132 342.7 
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FIGURES 
 
 
Figure 1: Clinic Comparison of SAgALABL-PLP to a mixture of SAgALABL and SAgAPLP.  The data suggest  the mixture 
of homopolymers performed similarly  to SAgALABL-PLP and PLP-BPI controls in (A) clinical disease score and (B) % 
change in body weight.  
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Figure 2: Comparison of clinical performance of SAgAs displaying MOG antigen in PLP induced EAE versus 
negative control (PBS).  The data show that SAgAMOG-PLP and SAgALABL-MOG performed significantly better than PBS 
control in (A) clinical disease score, (B) % change in body weight, and (C) incidence of disease. 
 
